JP2019505568A - Pad4の二環式阻害剤 - Google Patents
Pad4の二環式阻害剤 Download PDFInfo
- Publication number
- JP2019505568A JP2019505568A JP2018549402A JP2018549402A JP2019505568A JP 2019505568 A JP2019505568 A JP 2019505568A JP 2018549402 A JP2018549402 A JP 2018549402A JP 2018549402 A JP2018549402 A JP 2018549402A JP 2019505568 A JP2019505568 A JP 2019505568A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolo
- mmol
- cyclopropylmethyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 title claims abstract description 65
- 101150094373 Padi4 gene Proteins 0.000 title claims abstract description 65
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 title claims abstract description 65
- 239000003112 inhibitor Substances 0.000 title abstract description 23
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 299
- 239000000203 mixture Substances 0.000 claims abstract description 177
- 150000001875 compounds Chemical class 0.000 claims abstract description 156
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 54
- 201000010099 disease Diseases 0.000 claims abstract description 45
- -1 2 - cyclopropyl Chemical group 0.000 claims description 112
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 73
- 150000003839 salts Chemical class 0.000 claims description 56
- 125000001931 aliphatic group Chemical group 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 47
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 125000001153 fluoro group Chemical group F* 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 201000004681 Psoriasis Diseases 0.000 claims description 21
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 20
- 239000011737 fluorine Substances 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 16
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 206010047115 Vasculitis Diseases 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 11
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 4
- 208000027932 Collagen disease Diseases 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000037487 Endotoxemia Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims description 4
- 208000004852 Lung Injury Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 206010035742 Pneumonitis Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 206010002022 amyloidosis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 231100000515 lung injury Toxicity 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims description 2
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims description 2
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000020576 Adrenal disease Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- 241001475178 Dira Species 0.000 claims description 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims description 2
- 206010015287 Erythropenia Diseases 0.000 claims description 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010051606 Necrotising colitis Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010070594 PFAPA syndrome Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 241001442654 Percnon planissimum Species 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039792 Seborrhoea Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010040829 Skin discolouration Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
- 208000008526 Wells syndrome Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 201000004018 childhood brain stem glioma Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 201000007717 corneal ulcer Diseases 0.000 claims description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 claims description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims description 2
- 208000030941 fetal growth restriction Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 210000004276 hyalin Anatomy 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000003265 lymphadenitis Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 230000010346 psychosocial stress Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 201000011275 Epicondylitis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 208000025255 bacterial arthritis Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000002561 chemical irritant Substances 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 256
- 239000000243 solution Substances 0.000 description 186
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 173
- 230000014759 maintenance of location Effects 0.000 description 167
- 239000011541 reaction mixture Substances 0.000 description 167
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 140
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 129
- 235000019439 ethyl acetate Nutrition 0.000 description 125
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 118
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 100
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 90
- 235000002639 sodium chloride Nutrition 0.000 description 85
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 85
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 76
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 67
- 239000000843 powder Substances 0.000 description 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 61
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 58
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 238000003818 flash chromatography Methods 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 44
- 229910052938 sodium sulfate Inorganic materials 0.000 description 44
- 235000011152 sodium sulphate Nutrition 0.000 description 44
- 229920006395 saturated elastomer Polymers 0.000 description 42
- 239000002904 solvent Substances 0.000 description 42
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 41
- 239000012044 organic layer Substances 0.000 description 41
- 235000019441 ethanol Nutrition 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 35
- 238000011282 treatment Methods 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 32
- 239000000725 suspension Substances 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000010410 layer Substances 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 23
- 239000012071 phase Substances 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- 239000007821 HATU Substances 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000012298 atmosphere Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000001993 wax Substances 0.000 description 16
- 238000001514 detection method Methods 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 238000004296 chiral HPLC Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000013058 crude material Substances 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
- 239000005695 Ammonium acetate Substances 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 235000019257 ammonium acetate Nutrition 0.000 description 8
- 229940043376 ammonium acetate Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000006329 citrullination Effects 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 8
- CBIVEMGUNRNUEB-UHFFFAOYSA-N ethyl 1h-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2NC(C(=O)OCC)=CC2=C1 CBIVEMGUNRNUEB-UHFFFAOYSA-N 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- HIZRUIRMVQHKMB-UHFFFAOYSA-N methyl 3-amino-5-methoxy-4-(methylamino)benzoate Chemical compound NC=1C=C(C(=O)OC)C=C(C=1NC)OC HIZRUIRMVQHKMB-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- VRZCFBMOEOCOJX-UHFFFAOYSA-N 1-ethylpyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2N(CC)C(C(O)=O)=CC2=C1 VRZCFBMOEOCOJX-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 235000019502 Orange oil Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- TWMPSHBCLJOECE-UHFFFAOYSA-N ethyl 1-ethylpyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C(=O)OCC TWMPSHBCLJOECE-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000003365 glass fiber Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- YIRXEGUDDPQTBF-UHFFFAOYSA-N methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate Chemical compound CNC1=C(OC)C=C(C(=O)OC)C=C1[N+]([O-])=O YIRXEGUDDPQTBF-UHFFFAOYSA-N 0.000 description 6
- QNYHMMOXMRPWTK-UHFFFAOYSA-N methyl 4-chloro-3-methoxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC(OC)=C(Cl)C([N+]([O-])=O)=C1 QNYHMMOXMRPWTK-UHFFFAOYSA-N 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000010502 orange oil Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- IVPDDMDSKHMWTL-NTKDMRAZSA-N tert-butyl (3aR,7aS)-6-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carbonyl]-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@@H]2[C@H](CC1)CCN2C(=O)OC(C)(C)C)OC IVPDDMDSKHMWTL-NTKDMRAZSA-N 0.000 description 6
- IVPDDMDSKHMWTL-UHFFFAOYSA-N tert-butyl 6-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carbonyl]-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC2C(CC1)CCN2C(=O)OC(C)(C)C)OC IVPDDMDSKHMWTL-UHFFFAOYSA-N 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- XGXSQSNIYVCGBD-UHFFFAOYSA-N 1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C(=O)O XGXSQSNIYVCGBD-UHFFFAOYSA-N 0.000 description 5
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 5
- ZCEQCADZRBENIM-UHFFFAOYSA-N CN1C(C(N(CC2CC2)C2=N3)=CC2=CC=C3OC)=NC2=C1C(OC)=CC(C=O)=C2 Chemical compound CN1C(C(N(CC2CC2)C2=N3)=CC2=CC=C3OC)=NC2=C1C(OC)=CC(C=O)=C2 ZCEQCADZRBENIM-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 5
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 5
- YQDHCCVUYCIGSW-LBPRGKRZSA-N ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate Chemical compound NC(=N)NCCC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC=C1 YQDHCCVUYCIGSW-LBPRGKRZSA-N 0.000 description 5
- BPRJJYZQGGIDFY-UHFFFAOYSA-N methyl 2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC BPRJJYZQGGIDFY-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 5
- 102000001235 protein arginine deiminase Human genes 0.000 description 5
- 108060006632 protein arginine deiminase Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- KGHHUYBCGJDOKW-UHFFFAOYSA-N 1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC2C(CC1)CCN2)OC KGHHUYBCGJDOKW-UHFFFAOYSA-N 0.000 description 4
- UHXBVPPIZRLARP-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-oxo-7H-pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)O)C(=O)O UHXBVPPIZRLARP-UHFFFAOYSA-N 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- CBDNKFZFXXJIHU-UHFFFAOYSA-N 2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carboxylic acid Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)O)OC CBDNKFZFXXJIHU-UHFFFAOYSA-N 0.000 description 4
- IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- KGHHUYBCGJDOKW-UZLBHIALSA-N [(3aR,7aR)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N1CC[C@H]2[C@@H]1CN(CC2)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC)C)C(=C1)OC KGHHUYBCGJDOKW-UZLBHIALSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960002173 citrulline Drugs 0.000 description 4
- 235000013477 citrulline Nutrition 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 4
- UOQRESVEXATCGD-UHFFFAOYSA-N methyl 3-amino-4-(methylamino)benzoate Chemical compound CNC1=CC=C(C(=O)OC)C=C1N UOQRESVEXATCGD-UHFFFAOYSA-N 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- IVPDDMDSKHMWTL-CYFREDJKSA-N tert-butyl (3aS,7aR)-6-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carbonyl]-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@H]2[C@@H](CC1)CCN2C(=O)OC(C)(C)C)OC IVPDDMDSKHMWTL-CYFREDJKSA-N 0.000 description 4
- KFOSBANHALBORK-UHFFFAOYSA-N tert-butyl 2,3,3a,4,5,6,7,7a-octahydropyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C1CNCC2N(C(=O)OC(C)(C)C)CCC21 KFOSBANHALBORK-UHFFFAOYSA-N 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- VXWQMLRHHBEIAG-XFZHLKPQSA-N (1R,4R,6S,7R)-7-bromo-6-methoxy-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptane Chemical compound Br[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2OC)[C@@H](C)C1=CC=CC=C1 VXWQMLRHHBEIAG-XFZHLKPQSA-N 0.000 description 3
- XMPKCWMQFYHZLB-UHFFFAOYSA-N 1-(benzenesulfonyl)-6-methoxypyrrolo[2,3-b]pyridine Chemical compound C12=NC(OC)=CC=C2C=CN1S(=O)(=O)C1=CC=CC=C1 XMPKCWMQFYHZLB-UHFFFAOYSA-N 0.000 description 3
- SNCOSQBXRXFZQN-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-fluoropyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)F)C(=O)O SNCOSQBXRXFZQN-UHFFFAOYSA-N 0.000 description 3
- FPHMKRMKSIKLKI-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1C)C=CC(=C2)C(=O)O FPHMKRMKSIKLKI-UHFFFAOYSA-N 0.000 description 3
- UHXWDTIHVOAUPV-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylic acid Chemical compound N=1C2=CC(C(O)=O)=CC=C2N(C)C=1C1=CC2=CC=CN=C2N1CC1CC1 UHXWDTIHVOAUPV-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WMKYKQWKLILFBM-UHFFFAOYSA-N 2h-pyridine-1-carboxylic acid Chemical compound OC(=O)N1CC=CC=C1 WMKYKQWKLILFBM-UHFFFAOYSA-N 0.000 description 3
- SGNWGZQUTZVGHM-UHFFFAOYSA-N 3-(hydroxymethyl)-1-methylcyclobutan-1-ol Chemical compound CC1(O)CC(CO)C1 SGNWGZQUTZVGHM-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 101100123053 Arabidopsis thaliana GSH1 gene Proteins 0.000 description 3
- 101100298888 Arabidopsis thaliana PAD2 gene Proteins 0.000 description 3
- MIJVDPNZMFXGKX-UHFFFAOYSA-N CN1C(C(N(CC2CC2)C2=N3)=CC2=CC=C3OC)=NC2=C1C=CC(C=O)=C2 Chemical compound CN1C(C(N(CC2CC2)C2=N3)=CC2=CC=C3OC)=NC2=C1C=CC(C=O)=C2 MIJVDPNZMFXGKX-UHFFFAOYSA-N 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101150092599 Padi2 gene Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100035735 Protein-arginine deiminase type-2 Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GSRMTIWYAKMYJP-LWSJSWBQSA-N [(1S,4R,6S,7R)-7-amino-6-hydroxy-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2O)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC GSRMTIWYAKMYJP-LWSJSWBQSA-N 0.000 description 3
- MMOLQKSKGTYMKM-UHFFFAOYSA-N [3-amino-4-(difluoromethoxy)piperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(C(CC1)OC(F)F)N)OC MMOLQKSKGTYMKM-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000001023 centrifugal evaporation Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- KLHNSMMPSKOUFX-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-6-methoxypyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C(=CC=2C1=NC(=CC=2)OC)C(=O)OCC KLHNSMMPSKOUFX-UHFFFAOYSA-N 0.000 description 3
- NIOVMVNMDNVMNG-UHFFFAOYSA-N ethyl 1-(cyclopropylmethyl)-6-(3,6-dihydro-2H-pyran-4-yl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)C=1CCOCC=1)C(=O)OCC NIOVMVNMDNVMNG-UHFFFAOYSA-N 0.000 description 3
- RYORCZSKAFMRTG-UHFFFAOYSA-N ethyl 1-(cyclopropylmethyl)-6-(oxan-4-yl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)C1CCOCC1)C(=O)OCC RYORCZSKAFMRTG-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- BWFDHIHCENMVTJ-UHFFFAOYSA-N methyl 1-(cyclopropylmethyl)-6-(2-hydroxypropan-2-yl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)C(C)(C)O)C(=O)OC BWFDHIHCENMVTJ-UHFFFAOYSA-N 0.000 description 3
- NXXJMTVAGKOKDC-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-(2-methylsulfinylethyl)benzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CCS(=O)C)C(=CC(=C2)C(=O)OC)OC NXXJMTVAGKOKDC-UHFFFAOYSA-N 0.000 description 3
- BHNYROMTUGWVQF-UHFFFAOYSA-N methyl 2-methoxy-4-(methylamino)-5-nitrobenzoate Chemical compound CNC1=CC(OC)=C(C(=O)OC)C=C1[N+]([O-])=O BHNYROMTUGWVQF-UHFFFAOYSA-N 0.000 description 3
- XJHZLZSVKQRXQB-UHFFFAOYSA-N methyl 2-methyl-4-(methylamino)-5-nitrobenzoate Chemical compound CNC1=CC(C)=C(C(=O)OC)C=C1[N+]([O-])=O XJHZLZSVKQRXQB-UHFFFAOYSA-N 0.000 description 3
- FYTIYCPRZGJJBQ-UHFFFAOYSA-N methyl 3-(difluoromethoxy)-4-(methylamino)-5-nitrobenzoate Chemical compound FC(OC=1C=C(C(=O)OC)C=C(C=1NC)[N+](=O)[O-])F FYTIYCPRZGJJBQ-UHFFFAOYSA-N 0.000 description 3
- IFUILPSXLTUJRU-UHFFFAOYSA-N methyl 3-amino-5-(difluoromethoxy)-4-(methylamino)benzoate Chemical compound NC=1C=C(C(=O)OC)C=C(C=1NC)OC(F)F IFUILPSXLTUJRU-UHFFFAOYSA-N 0.000 description 3
- BIWQGVYJGCYAPF-UHFFFAOYSA-N methyl 4-(ethylamino)-3-methoxy-5-nitrobenzoate Chemical compound C(C)NC1=C(C=C(C(=O)OC)C=C1[N+](=O)[O-])OC BIWQGVYJGCYAPF-UHFFFAOYSA-N 0.000 description 3
- RUJMPEWZLDVEAV-UHFFFAOYSA-N methyl 4-(methylamino)-3-nitrobenzoate Chemical compound CNC1=CC=C(C(=O)OC)C=C1[N+]([O-])=O RUJMPEWZLDVEAV-UHFFFAOYSA-N 0.000 description 3
- CIHZVGOQXLAKQB-UHFFFAOYSA-N methyl 4-chloro-3-(difluoromethoxy)-5-nitrobenzoate Chemical compound ClC1=C(C=C(C(=O)OC)C=C1[N+](=O)[O-])OC(F)F CIHZVGOQXLAKQB-UHFFFAOYSA-N 0.000 description 3
- UISBPFIZGNICMM-UHFFFAOYSA-N methyl 4-chloro-3-hydroxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC(O)=C(Cl)C([N+]([O-])=O)=C1 UISBPFIZGNICMM-UHFFFAOYSA-N 0.000 description 3
- GPVMPPDFEOSPND-UHFFFAOYSA-N methyl 5-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(NC(=O)OC(C)(C)C)C=N1 GPVMPPDFEOSPND-UHFFFAOYSA-N 0.000 description 3
- XCQWRMHWLUCBTM-UHFFFAOYSA-N methyl 5-amino-2-methyl-4-(methylamino)benzoate Chemical compound CNC1=CC(C)=C(C(=O)OC)C=C1N XCQWRMHWLUCBTM-UHFFFAOYSA-N 0.000 description 3
- UMMYEULACVGVAX-UHFFFAOYSA-N methyl 7-(cyclopropylmethyl)-2-methoxypyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound C1(CC1)CN1C(=CC2=C1N=C(N=C2)OC)C(=O)OC UMMYEULACVGVAX-UHFFFAOYSA-N 0.000 description 3
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- MFJGBXGEPHCJDK-AREMUKBSSA-N phenyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-3-methyl-6-[(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carbonyl]benzimidazole-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)C(=O)OC1=CC=CC=C1 MFJGBXGEPHCJDK-AREMUKBSSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- AYLPJYFVRJVMCV-UHFFFAOYSA-N tert-butyl 6-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-(difluoromethoxy)-1-methylbenzimidazole-5-carbonyl]-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC2C1CN(CC2)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC(F)F AYLPJYFVRJVMCV-UHFFFAOYSA-N 0.000 description 3
- RYEXMULUOFOHBW-OPRDCNLKSA-N tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]-N-methylcarbamate Chemical compound CN([C@@H]1[C@@H]2CC[C@H]1NC2)C(=O)OC(C)(C)C RYEXMULUOFOHBW-OPRDCNLKSA-N 0.000 description 3
- NHVLLFXVGDDNPB-DTWKUNHWSA-N tert-butyl N-[(3S,4R)-4-methoxypiperidin-3-yl]carbamate Chemical compound CO[C@H]1[C@H](CNCC1)NC(OC(C)(C)C)=O NHVLLFXVGDDNPB-DTWKUNHWSA-N 0.000 description 3
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 3
- LPFFLZUJBODPOB-UHFFFAOYSA-N tert-butyl n-[6-(hydroxymethyl)piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(CO)NC1 LPFFLZUJBODPOB-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- PIZQWRXTMGASCZ-UHFFFAOYSA-N (1-methylcyclopropyl)methanol Chemical compound OCC1(C)CC1 PIZQWRXTMGASCZ-UHFFFAOYSA-N 0.000 description 2
- LIVWREIOAKDGPB-LCGIIJARSA-N (1R,4R,7R)-N,N-dimethyl-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-amine Chemical compound CN([C@H]1[C@@H]2N(C[C@H]1CC2)[C@@H](C)C1=CC=CC=C1)C LIVWREIOAKDGPB-LCGIIJARSA-N 0.000 description 2
- DLUUSWSTJVGDEY-XFZHLKPQSA-N (1S,4R,6S,7R)-6-methoxy-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-amine Chemical compound CO[C@H]1C[C@@H]2CN([C@H]1[C@@H]2N)[C@@H](C)C1=CC=CC=C1 DLUUSWSTJVGDEY-XFZHLKPQSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- REHVFNXZZYDMQS-UHFFFAOYSA-N (3-amino-4-fluoropiperidin-1-yl)-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(C(CC1)F)N)OC REHVFNXZZYDMQS-UHFFFAOYSA-N 0.000 description 2
- AAFOPOMMHLDGMW-UHFFFAOYSA-N (3-azido-4-fluoropiperidin-1-yl)-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N(=[N+]=[N-])C1CN(CCC1F)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC AAFOPOMMHLDGMW-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- KRLJESUFNYLZGV-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C(=O)O KRLJESUFNYLZGV-UHFFFAOYSA-N 0.000 description 2
- FDJYMRCIYZVMMV-UHFFFAOYSA-N 1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-5-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-3-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)NC1CC(CN(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC)C(=O)O FDJYMRCIYZVMMV-UHFFFAOYSA-N 0.000 description 2
- LOGZOMIRLZGSSW-UHFFFAOYSA-N 1-o-benzyl 3-o-methyl 5-hydroxypiperidine-1,3-dicarboxylate Chemical compound C1C(C(=O)OC)CC(O)CN1C(=O)OCC1=CC=CC=C1 LOGZOMIRLZGSSW-UHFFFAOYSA-N 0.000 description 2
- UDAMGOKZZIHJHJ-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1C)C(=CC(=C2)C(=O)O)OC UDAMGOKZZIHJHJ-UHFFFAOYSA-N 0.000 description 2
- MMEYYNRWLDAPBA-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-(difluoromethoxy)-1-methylbenzimidazole-5-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)O)OC(F)F MMEYYNRWLDAPBA-UHFFFAOYSA-N 0.000 description 2
- FRQAJXLMICKCKE-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylic acid Chemical compound CN1C=2C(OC)=CC(C(O)=O)=CC=2N=C1C1=CC2=CC=CN=C2N1CC1CC1 FRQAJXLMICKCKE-UHFFFAOYSA-N 0.000 description 2
- PFUUAMJHVHUCME-UHFFFAOYSA-N 2-[5-bromo-1-(cyclopropylmethyl)indol-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylic acid Chemical compound BrC=1C=C2C=C(N(C2=CC=1)CC1CC1)C1=NC2=C(N1C)C(=CC(=C2)C(=O)O)OC PFUUAMJHVHUCME-UHFFFAOYSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HSTPJHPMSMUUQX-UHFFFAOYSA-N 5-amino-1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]piperidine-3-carbonitrile Chemical compound NC1CC(CN(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC)C#N HSTPJHPMSMUUQX-UHFFFAOYSA-N 0.000 description 2
- NJYUDPMSOPJZPL-UHFFFAOYSA-N 5-bromo-1-(cyclopropylmethyl)indole-2-carbaldehyde Chemical compound BrC=1C=C2C=C(N(C2=CC=1)CC1CC1)C=O NJYUDPMSOPJZPL-UHFFFAOYSA-N 0.000 description 2
- CSTHCPDMBGXFOF-UHFFFAOYSA-N 6-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound ClC1=CC=C2C(=N1)N(C(=C2)C(=O)O)CC1CC1 CSTHCPDMBGXFOF-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HCAJXVNBSQVXNN-JKSUJKDBSA-N C(C)(C)(C)OC(=O)N[C@H]1CN(CC[C@H]1OC)C(=O)OCC1=CC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)N[C@H]1CN(CC[C@H]1OC)C(=O)OCC1=CC=CC=C1 HCAJXVNBSQVXNN-JKSUJKDBSA-N 0.000 description 2
- FTVYJIDTQMKIRU-HUUCEWRRSA-N C(C1=CC=CC=C1)OC(=O)N[C@@H]1CN(CC[C@H]1O)C(=O)OC(C)(C)C Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H]1CN(CC[C@H]1O)C(=O)OC(C)(C)C FTVYJIDTQMKIRU-HUUCEWRRSA-N 0.000 description 2
- CKHPXYHNPLWERK-UHFFFAOYSA-N C1(CC1)C(C)N1C(=CC=2C1=NC=CC=2)C(=O)OCC Chemical compound C1(CC1)C(C)N1C(=CC=2C1=NC=CC=2)C(=O)OCC CKHPXYHNPLWERK-UHFFFAOYSA-N 0.000 description 2
- FNAXGCPVTUFBEI-JKSHRDEXSA-N CN1C2=C(C=C(C=C2OC(F)F)C(=O)N3CC[C@H]4CCN[C@H]4C3)N=C1C5=CC6=C(N5CC7CC7)N=CC=C6.Cl Chemical compound CN1C2=C(C=C(C=C2OC(F)F)C(=O)N3CC[C@H]4CCN[C@H]4C3)N=C1C5=CC6=C(N5CC7CC7)N=CC=C6.Cl FNAXGCPVTUFBEI-JKSHRDEXSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- JKTUAKXOCCWTQF-GMUIIQOCSA-N Cl.N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC3)N2CC2CC2)C)C(=C1)C(=O)N Chemical compound Cl.N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC3)N2CC2CC2)C)C(=C1)C(=O)N JKTUAKXOCCWTQF-GMUIIQOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000577121 Homo sapiens Monocarboxylate transporter 3 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
- 102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- YQVDVFBJBRYOLG-OWZGOFHBSA-N N'-[(7R)-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-yl]ethanimidamide Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C2CCC(C1)[C@H]2NC(C)=N)OC YQVDVFBJBRYOLG-OWZGOFHBSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GPUJJQYICRYIOJ-WOJBJXKFSA-N [(2R,5R)-5-amino-2-(hydroxymethyl)piperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@@H]1CC[C@@H](N(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC)CO GPUJJQYICRYIOJ-WOJBJXKFSA-N 0.000 description 2
- GPUJJQYICRYIOJ-VQTJNVASSA-N [(2R,5S)-5-amino-2-(hydroxymethyl)piperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@H]1CC[C@@H](N(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC)CO GPUJJQYICRYIOJ-VQTJNVASSA-N 0.000 description 2
- KGHHUYBCGJDOKW-OXJNMPFZSA-N [(3aS,7aS)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound CCN1C(=CC2=C1N=CC=C2)C1=NC2=CC(=CC(OC)=C2N1C)C(=O)N1CC[C@@H]2CCN[C@@H]2C1 KGHHUYBCGJDOKW-OXJNMPFZSA-N 0.000 description 2
- LCDXXVGITLYHDX-VASSOYJASA-N [(3aS,7aS)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazol-5-yl]methanone hydrochloride Chemical compound Cl.CCn1c(cc2cccnc12)-c1nc2cc(cc(OC)c2n1C)C(=O)N1CC[C@@H]2CCN[C@@H]2C1 LCDXXVGITLYHDX-VASSOYJASA-N 0.000 description 2
- DFUGXYQHKOVWCD-OFNKIYASSA-N [(4aR,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@@H]2OCCN[C@@H]2C1)OC DFUGXYQHKOVWCD-OFNKIYASSA-N 0.000 description 2
- KIVBPAQOLGNWNG-UHFFFAOYSA-N [1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-4-fluoropiperidin-3-yl] methanesulfonate Chemical compound CS(=O)(=O)OC1CN(CCC1F)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC KIVBPAQOLGNWNG-UHFFFAOYSA-N 0.000 description 2
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HHWWAHRPWPWFAW-KAYWLYCHSA-N benzyl N-[(3R,5R)-1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-5-hydroxypiperidin-3-yl]-N-methylcarbamate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@@H](C[C@H](C1)O)N(C(OCC1=CC=CC=C1)=O)C)OC HHWWAHRPWPWFAW-KAYWLYCHSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- CGJBOYJQJQGXKI-UHFFFAOYSA-N ethyl 1-(cyclopropylmethyl)-3-fluoropyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=C(C=2C1=NC=CC=2)F)C(=O)OCC CGJBOYJQJQGXKI-UHFFFAOYSA-N 0.000 description 2
- FATAZSYHORQGKJ-UHFFFAOYSA-N ethyl 1-(cyclopropylmethyl)-6-morpholin-4-ylpyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)N1CCOCC1)C(=O)OCC FATAZSYHORQGKJ-UHFFFAOYSA-N 0.000 description 2
- IWFLDXWAQVHCJP-UHFFFAOYSA-N ethyl 6-methoxy-1H-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound COC1=CC=C2C(=N1)NC(=C2)C(=O)OCC IWFLDXWAQVHCJP-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- LAUJAFDRYDJRCX-FIBGUPNXSA-N methyl 1-(cyclopropylmethyl)-6-(trideuteriomethoxy)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC([2H])([2H])[2H])C(=O)OC LAUJAFDRYDJRCX-FIBGUPNXSA-N 0.000 description 2
- DITCHUILFSNGME-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)c1ccc2n(C)c(nc2c1)-c1cc2cccnc2n1CC1CC1 DITCHUILFSNGME-UHFFFAOYSA-N 0.000 description 2
- CDQLJLOWZRQQMH-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-(2-methylsulfonylethyl)benzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CCS(=O)(=O)C)C(=CC(=C2)C(=O)OC)OC CDQLJLOWZRQQMH-UHFFFAOYSA-N 0.000 description 2
- ARZLFQAOQCUKKV-UHFFFAOYSA-N methyl 2-[5-bromo-1-(cyclopropylmethyl)indol-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC2=C(N(C(=N2)C=2N(C3=CC=C(C=C3C=2)Br)CC2CC2)C)C(=C1)OC ARZLFQAOQCUKKV-UHFFFAOYSA-N 0.000 description 2
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 description 2
- DGPNDQDDHSRHDM-UHFFFAOYSA-N methyl 3-amino-4-(ethylamino)-5-methoxybenzoate Chemical compound NC=1C=C(C(=O)OC)C=C(C=1NCC)OC DGPNDQDDHSRHDM-UHFFFAOYSA-N 0.000 description 2
- IYCXMARYOQUAAF-UHFFFAOYSA-N methyl 5-amino-2-methoxy-4-(methylamino)benzoate Chemical compound CNC1=CC(OC)=C(C(=O)OC)C=C1N IYCXMARYOQUAAF-UHFFFAOYSA-N 0.000 description 2
- ZAUFCVXOKIPCKG-UHFFFAOYSA-N methyl 5-hydroxypiperidine-3-carboxylate Chemical compound COC(=O)C1CNCC(O)C1 ZAUFCVXOKIPCKG-UHFFFAOYSA-N 0.000 description 2
- GLGJCZQHYJZQMC-UHFFFAOYSA-N methyl 5-phenyl-1h-pyrrole-2-carboxylate Chemical compound N1C(C(=O)OC)=CC=C1C1=CC=CC=C1 GLGJCZQHYJZQMC-UHFFFAOYSA-N 0.000 description 2
- NLUGSFRIVMGLLW-UHFFFAOYSA-N methyl 6-(difluoromethoxy)-1-ethylpyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound FC(OC1=CC=C2C(=N1)N(C(=C2)C(=O)OC)CC)F NLUGSFRIVMGLLW-UHFFFAOYSA-N 0.000 description 2
- ZOFZLOBUOUKGNH-UHFFFAOYSA-N methyl 6-acetyl-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C(C)(=O)C1=CC=C2C(=N1)N(C(=C2)C(=O)OC)CC1CC1 ZOFZLOBUOUKGNH-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- LUQURLQDYAJECW-HTQZYQBOSA-N tert-butyl (3r,4r)-3-amino-4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)[C@H](N)C1 LUQURLQDYAJECW-HTQZYQBOSA-N 0.000 description 2
- QXQXWXVCWJRSLJ-UHFFFAOYSA-N tert-butyl 1-(cyclopropylmethyl)-4-fluoropyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2F)C(=O)OC(C)(C)C QXQXWXVCWJRSLJ-UHFFFAOYSA-N 0.000 description 2
- PZIYZIXZDKWRJK-UHFFFAOYSA-N tert-butyl 1-(cyclopropylmethyl)-6-fluoropyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)F)C(=O)OC(C)(C)C PZIYZIXZDKWRJK-UHFFFAOYSA-N 0.000 description 2
- JGUANVOPPVXJBQ-UHFFFAOYSA-N tert-butyl 6-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound ClC1=CC=C2C(=N1)N(C(=C2)C(=O)OC(C)(C)C)CC1CC1 JGUANVOPPVXJBQ-UHFFFAOYSA-N 0.000 description 2
- SJJQNQMKFYBMBR-RKTXRCNFSA-N tert-butyl N-[(1R,4R,7R)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@H](C)N1[C@@H]2CC[C@H](C1)[C@H]2NC(OC(C)(C)C)=O SJJQNQMKFYBMBR-RKTXRCNFSA-N 0.000 description 2
- WWVZQTWABDJJAR-UTINFBMNSA-N tert-butyl N-[(1S,4R,6S,7R)-6-methoxy-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound CO[C@H]1C[C@@H]2CN[C@H]1[C@@H]2NC(OC(C)(C)C)=O WWVZQTWABDJJAR-UTINFBMNSA-N 0.000 description 2
- HRVVSQCKPAPUSV-DZOHQFGASA-N tert-butyl N-methyl-N-[(1R,4R,7R)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-yl]carbamate Chemical compound CN(C(OC(C)(C)C)=O)[C@H]1[C@@H]2N(C[C@H]1CC2)[C@@H](C)C1=CC=CC=C1 HRVVSQCKPAPUSV-DZOHQFGASA-N 0.000 description 2
- FVXMQFNZAQVKAK-UHFFFAOYSA-N tert-butyl n-[6-(hydroxymethyl)pyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(CO)N=C1 FVXMQFNZAQVKAK-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JUWCSSFZMOYKNB-IGHBBLSQSA-N (1R,4R,7R)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-amine Chemical compound C1(=CC=CC=C1)[C@H](C)N1[C@@H]2CC[C@H](C1)[C@H]2N JUWCSSFZMOYKNB-IGHBBLSQSA-N 0.000 description 1
- SRATWSIJRMRDIK-ACNHANLQSA-N (1R,4R,7R)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptan-7-amine dihydrochloride Chemical compound Cl.Cl.C[C@H](N1C[C@H]2CC[C@@H]1[C@@H]2N)c1ccccc1 SRATWSIJRMRDIK-ACNHANLQSA-N 0.000 description 1
- GLGPDOYNZDNHCK-IGHBBLSQSA-N (1R,4R,7R)-7-bromo-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]heptane Chemical compound Br[C@H]1[C@@H]2N(C[C@H]1CC2)[C@@H](C)C1=CC=CC=C1 GLGPDOYNZDNHCK-IGHBBLSQSA-N 0.000 description 1
- CYUSELKAVBPPEQ-OFOUDFFZSA-N (1S,2R,8R)-10-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-5-oxa-3,10-diazatricyclo[4.4.0.02,8]decan-4-one Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@H]2CC3OC(N[C@H]2[C@H]13)=O)OC CYUSELKAVBPPEQ-OFOUDFFZSA-N 0.000 description 1
- GAZVSOQUFLIBJQ-BYNIDDHOSA-M (2s,3s,4s,5r,6s)-6-[(5-bromo-6-chloro-1h-indol-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound O1[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CNC2=CC(Cl)=C(Br)C=C12 GAZVSOQUFLIBJQ-BYNIDDHOSA-M 0.000 description 1
- YHFWUKDGIOFJKV-UHFFFAOYSA-N (3-amino-4-methoxypiperidin-1-yl)-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1CCN(CC1N)C(=O)C1=CC=C2N(C)C(=NC2=C1)C1=CC2=C(N=CC=C2)N1CC1CC1 YHFWUKDGIOFJKV-UHFFFAOYSA-N 0.000 description 1
- YZSCSYINMAQFSC-KKSFZXQISA-N (3aS,7aR)-6-[2-(1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carbonyl]-3,3a,4,5,7,7a-hexahydro-2H-pyrrolo[2,3-c]pyridine-1-carboxylic acid Chemical compound CCn1c(cc2cccnc12)-c1nc2cc(cc(OC)c2n1C)C(=O)N1CC[C@H]2CCN([C@H]2C1)C(O)=O YZSCSYINMAQFSC-KKSFZXQISA-N 0.000 description 1
- IHABLPPPFMZYCQ-UHFFFAOYSA-N 1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl-[2-[7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidin-6-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC2=C1N=CN=C2)C1=NC2=C(N1C)C=CC(=C2)C(=O)N1CC2C(CC1)CCN2 IHABLPPPFMZYCQ-UHFFFAOYSA-N 0.000 description 1
- MBJYGYANNLFRAN-UHFFFAOYSA-N 1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl-[2-[7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC2=C1N=CN=C2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC2C(CC1)CCN2)OC MBJYGYANNLFRAN-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KRLJESUFNYLZGV-FIBGUPNXSA-N 1-(cyclopropylmethyl)-6-(trideuteriomethoxy)pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC([2H])([2H])[2H])C(=O)O KRLJESUFNYLZGV-FIBGUPNXSA-N 0.000 description 1
- ABDJJUHXFYVFBK-UHFFFAOYSA-N 1-[(3-hydroxy-3-methylcyclobutyl)methyl]pyrrolo[2,3-b]pyridine-2-carboxylic acid Chemical compound CC1(CC(C1)CN2C(=CC3=C2N=CC=C3)C(=O)O)O ABDJJUHXFYVFBK-UHFFFAOYSA-N 0.000 description 1
- DKKVKJZXOBFLRY-UHFFFAOYSA-N 1-cyclopropylethanol Chemical compound CC(O)C1CC1 DKKVKJZXOBFLRY-UHFFFAOYSA-N 0.000 description 1
- FGYADSCZTQOAFK-UHFFFAOYSA-N 1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C=NC2=C1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QRGOJTWDYRFKJI-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC=CC2=C1NC=N2 QRGOJTWDYRFKJI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
- QSCYAEYBRYQPPK-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-ethyl-7-methoxybenzimidazole-5-carboxylic acid Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CC)C(=CC(=C2)C(=O)O)OC QSCYAEYBRYQPPK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MKWDDRHHVWEKMO-OJBIZCRPSA-N 2-[5-[(1S,4R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methylbenzimidazol-2-yl]-1-(cyclopropylmethyl)indole-5-carbonitrile Chemical compound NC1[C@H]2N(C[C@H]1CC2)C(=O)C1=CC2=C(N(C(=N2)C=2N(C3=CC=C(C=C3C=2)C#N)CC2CC2)C)C(=C1)OC MKWDDRHHVWEKMO-OJBIZCRPSA-N 0.000 description 1
- FCBUUWHXNWETAS-LRZQZFAJSA-N 2-[[(1S,4R,6S,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl]oxy]acetonitrile Chemical compound COC1=C2N(C)C(=NC2=CC(=C1)C(=O)N1C[C@H]2C[C@H](OCC#N)[C@@H]1[C@@H]2N)C1=CC2=CC=CN=C2N1CC1CC1 FCBUUWHXNWETAS-LRZQZFAJSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- MNOONJNILVDLSW-UHFFFAOYSA-N 2-chloro-2,2-difluoro-1-phenylethanone Chemical compound FC(F)(Cl)C(=O)C1=CC=CC=C1 MNOONJNILVDLSW-UHFFFAOYSA-N 0.000 description 1
- ZOGZOXRETBBBJI-UHFFFAOYSA-N 2-cyclopropylethanamine Chemical compound NCCC1CC1 ZOGZOXRETBBBJI-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WIJAEEHYEQAEOD-UHFFFAOYSA-N 3-amino-4-(ethylamino)-5-methoxybenzoic acid Chemical compound CCNc1c(N)cc(cc1OC)C(O)=O WIJAEEHYEQAEOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- GJFHHQJYZGSYSR-UHFFFAOYSA-N 3-hydroxy-3-methylcyclobutane-1-carboxylic acid Chemical compound CC1(O)CC(C(O)=O)C1 GJFHHQJYZGSYSR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- IXDXXQMPGDUEJK-UHFFFAOYSA-N 4-methoxypiperidin-3-amine Chemical compound COC1CCNCC1N IXDXXQMPGDUEJK-UHFFFAOYSA-N 0.000 description 1
- CFABANPJKXPUFN-UHFFFAOYSA-N 5-bromo-1h-indole-2-carbaldehyde Chemical compound BrC1=CC=C2NC(C=O)=CC2=C1 CFABANPJKXPUFN-UHFFFAOYSA-N 0.000 description 1
- YEQVNAGNEONSTR-UHFFFAOYSA-N 5-phenyl-1h-pyrrole-2-carboxylic acid Chemical compound N1C(C(=O)O)=CC=C1C1=CC=CC=C1 YEQVNAGNEONSTR-UHFFFAOYSA-N 0.000 description 1
- IGZHNWFLHSANSN-UHFFFAOYSA-N 6-bromo-1h-indole-2-carbaldehyde Chemical compound BrC1=CC=C2C=C(C=O)NC2=C1 IGZHNWFLHSANSN-UHFFFAOYSA-N 0.000 description 1
- LNEHZEFKSUBWTA-UHFFFAOYSA-N 6-methoxy-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC=C2C=CNC2=N1 LNEHZEFKSUBWTA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HHZKYTGSMOMGOQ-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1=CN=C2NC(C(=O)O)=CC2=C1 HHZKYTGSMOMGOQ-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QECQSKAVFWWIRI-UHFFFAOYSA-N C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(CC(C1)NC)O)OC Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(CC(C1)NC)O)OC QECQSKAVFWWIRI-UHFFFAOYSA-N 0.000 description 1
- CLHTUMUMKFSRPZ-HUUCEWRRSA-N CC(C)(C)N(CC[C@H]1O)C[C@H]1NC(OCC1=CC=CC=C1)=O Chemical compound CC(C)(C)N(CC[C@H]1O)C[C@H]1NC(OCC1=CC=CC=C1)=O CLHTUMUMKFSRPZ-HUUCEWRRSA-N 0.000 description 1
- UFUQJINPDFAPPG-UHFFFAOYSA-N CC1(CC1)CN1C(=CC=2C1=NC=CC=2)C(=O)OCC Chemical compound CC1(CC1)CN1C(=CC=2C1=NC=CC=2)C(=O)OCC UFUQJINPDFAPPG-UHFFFAOYSA-N 0.000 description 1
- AOJMAZYDUPSDBG-FSRHSHDFSA-N CC1=CC2=C(C=C1C(=O)N3CCC[C@H](C3)N)N=C(N2C)C4=CC5=C(N4CC6CC6)N=CC=C5.Cl Chemical compound CC1=CC2=C(C=C1C(=O)N3CCC[C@H](C3)N)N=C(N2C)C4=CC5=C(N4CC6CC6)N=CC=C5.Cl AOJMAZYDUPSDBG-FSRHSHDFSA-N 0.000 description 1
- KLEUQLKJHSZZJB-UHFFFAOYSA-N CCC1=CC2=CC=CN=C2N1CC1(C)CC1 Chemical compound CCC1=CC2=CC=CN=C2N1CC1(C)CC1 KLEUQLKJHSZZJB-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LCDXXVGITLYHDX-UHFFFAOYSA-N Cl.C(C)N1C(=CC=2C1=NC=CC2)C2=NC1=C(N2C)C(=CC(=C1)C(=O)N1CC2C(CC1)CCN2)OC Chemical compound Cl.C(C)N1C(=CC=2C1=NC=CC2)C2=NC1=C(N2C)C(=CC(=C1)C(=O)N1CC2C(CC1)CCN2)OC LCDXXVGITLYHDX-UHFFFAOYSA-N 0.000 description 1
- DAKUYJBEZHMXKU-VEIFNGETSA-N Cl.C1(CC1)CN1C(=CC=2C1=NC=CC2)C2=NC1=C(N2CC)C(=CC(=C1)C(=O)N1C[C@@H](CCC1)N)OC Chemical compound Cl.C1(CC1)CN1C(=CC=2C1=NC=CC2)C2=NC1=C(N2CC)C(=CC(=C1)C(=O)N1C[C@@H](CCC1)N)OC DAKUYJBEZHMXKU-VEIFNGETSA-N 0.000 description 1
- FNAXGCPVTUFBEI-AYCGRUCCSA-N Cl.N1CC[C@H]2[C@H]1CN(CC2)C(=O)C2=CC1=C(N(C(=N1)C1=CC=3C(=NC=CC3)N1CC1CC1)C)C(=C2)OC(F)F Chemical compound Cl.N1CC[C@H]2[C@H]1CN(CC2)C(=O)C2=CC1=C(N(C(=N1)C1=CC=3C(=NC=CC3)N1CC1CC1)C)C(=C2)OC(F)F FNAXGCPVTUFBEI-AYCGRUCCSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 102100025721 Cytosolic carboxypeptidase 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000932634 Homo sapiens Cytosolic carboxypeptidase 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical class CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101001033011 Mus musculus Granzyme C Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- QJLGBYJFHXQVDL-DBXGMPFESA-N N-[(1S,4R,6S,7R)-7-amino-2-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-6-yl]propanamide Chemical compound N[C@H]1[C@@H]2N(C[C@H]1C[C@@H]2NC(CC)=O)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC QJLGBYJFHXQVDL-DBXGMPFESA-N 0.000 description 1
- GINGLZFZFUMFPW-LJQANCHMSA-N N-[2-[5-[(3R)-3-aminopiperidine-1-carbonyl]-1-methylbenzimidazol-2-yl]-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-4-yl]acetamide Chemical compound N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3NC(C)=O)N2CC2CC2)C)C=C1 GINGLZFZFUMFPW-LJQANCHMSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical class [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- KABBBXJFTRLKCT-BZNPZCIMSA-N O[C@H]1C[C@@H]2CN[C@H]1[C@@H]2NC(OC(C)(C)C)=O Chemical compound O[C@H]1C[C@@H]2CN[C@H]1[C@@H]2NC(OC(C)(C)C)=O KABBBXJFTRLKCT-BZNPZCIMSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TZLSWMXSGGRJAV-YIFZBPKDSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-3-fluoropyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC(=CC2=C1N(C)C(=N2)C1=C(F)C2=CC=CN=C2N1CC1CC1)C(=O)N1C[C@H]2CC[C@@H]1[C@@H]2N TZLSWMXSGGRJAV-YIFZBPKDSA-N 0.000 description 1
- XZNGYGQBGUHYPD-ZFUCPZCZSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-4-fluoropyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC(=CC2=C1N(C)C(=N2)C1=CC2=C(F)C=CN=C2N1CC1CC1)C(=O)N1C[C@H]2CC[C@@H]1[C@@H]2N XZNGYGQBGUHYPD-ZFUCPZCZSA-N 0.000 description 1
- VPJUTHQDFNZPLO-IOZGHAEBSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-6-(2-hydroxypropan-2-yl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@H]1[C@@H]2N(C[C@H]1CC2)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC(=CC=3)C(C)(C)O)N2CC2CC2)C)C(=C1)OC VPJUTHQDFNZPLO-IOZGHAEBSA-N 0.000 description 1
- IAXDEFWTMKCAAQ-LFGPKHSOSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-6-(oxan-4-yl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC(=CC2=C1N(C)C(=N2)C1=CC2=CC=C(N=C2N1CC1CC1)C1CCOCC1)C(=O)N1C[C@H]2CC[C@@H]1[C@@H]2N IAXDEFWTMKCAAQ-LFGPKHSOSA-N 0.000 description 1
- PNRNUKKEELBRJS-YPHOXKOZSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-6-(trideuteriomethoxy)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound [2H]C([2H])([2H])OC1=CC=C2C=C(N(CC3CC3)C2=N1)C1=NC2=C(C=CC(=C2)C(=O)N2C[C@H]3CC[C@@H]2[C@@H]3N)N1C PNRNUKKEELBRJS-YPHOXKOZSA-N 0.000 description 1
- XJWNDHZOCYPJHJ-ZDWFVDTJSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-6-fluoropyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC(=CC2=C1N(C)C(=N2)C1=CC2=CC=C(F)N=C2N1CC1CC1)C(=O)N1C[C@H]2CC[C@@H]1[C@@H]2N XJWNDHZOCYPJHJ-ZDWFVDTJSA-N 0.000 description 1
- NYPGHZHQLBLRJN-SZEHJLNQSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)-6-morpholin-4-ylpyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)N1CCOCC1)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC NYPGHZHQLBLRJN-SZEHJLNQSA-N 0.000 description 1
- ZYCSUAZOGSEKAE-SWBIDILNSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-(2-methylsulfinylethyl)benzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CCS(=O)C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC ZYCSUAZOGSEKAE-SWBIDILNSA-N 0.000 description 1
- HFAPIPAYLLZJJZ-OPJGWUQDSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-(2-methylsulfonylethyl)benzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CCS(=O)(=O)C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC HFAPIPAYLLZJJZ-OPJGWUQDSA-N 0.000 description 1
- SGCZUJNOMYYSEP-SOIKWTOOSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[6-(difluoromethoxy)-1-ethylpyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound FC(OC1=CC=C2C(=N1)N(C(=C2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC)CC)F SGCZUJNOMYYSEP-SOIKWTOOSA-N 0.000 description 1
- MAXHJWVLRQCZRC-CFCCAZDESA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[6-(difluoromethyl)-1-ethylpyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound FC(C1=CC=C2C(=N1)N(C(=C2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC)CC)F MAXHJWVLRQCZRC-CFCCAZDESA-N 0.000 description 1
- NTXQOIXRYSIRSA-YIFZBPKDSA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[7-(cyclopropylmethyl)-2-methoxypyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC2=C1N=C(N=C2)OC)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N)OC NTXQOIXRYSIRSA-YIFZBPKDSA-N 0.000 description 1
- AGMPFKDVFROQGJ-AYPBNUJASA-N [(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[7-(cyclopropylmethyl)-2-methylpyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC(=CC2=C1N(C)C(=N2)C1=CC2=CN=C(C)N=C2N1CC1CC1)C(=O)N1C[C@H]2CC[C@@H]1[C@@H]2N AGMPFKDVFROQGJ-AYPBNUJASA-N 0.000 description 1
- KJCVOFZEYWOPHS-MQVNCSNFSA-N [(1S,4R,6E,7R)-7-amino-6-methoxyimino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound CO\N=C1/C[C@@H]2CN([C@H]1[C@@H]2N)C(=O)C1=CC(OC)=C2N(C)C(=NC2=C1)C1=CC2=CC=CN=C2N1CC1CC1 KJCVOFZEYWOPHS-MQVNCSNFSA-N 0.000 description 1
- UFDCBOZTDHGPCJ-LTOPPJTRSA-N [(1S,4R,6S,7R)-7-amino-6-(dimethylamino)-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2N)N(C)C)OC UFDCBOZTDHGPCJ-LTOPPJTRSA-N 0.000 description 1
- VMRVHIQPFPOVCP-ZQJMJJNQSA-N [(1S,4R,6S,7R)-7-amino-6-methoxy-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2N)OC)OC VMRVHIQPFPOVCP-ZQJMJJNQSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- GPUJJQYICRYIOJ-UXHICEINSA-N [(2S,5R)-5-amino-2-(hydroxymethyl)piperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@@H]1CC[C@H](N(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)OC)CO GPUJJQYICRYIOJ-UXHICEINSA-N 0.000 description 1
- WYIQVGKULRBOHN-OAQYLSRUSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)-6-ethylpyrrolo[2,3-b]pyridin-2-yl]-1-ethyl-7-methoxybenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)CC)C1=NC2=C(N1CC)C(=CC(=C2)C(=O)N1C[C@@H](CCC1)N)OC WYIQVGKULRBOHN-OAQYLSRUSA-N 0.000 description 1
- QTWALFFTNWKHEQ-LJQANCHMSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-1-(2,2-difluoroethyl)-7-methoxybenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1CC(F)F)C(=CC(=C2)C(=O)N1C[C@@H](CCC1)N)OC QTWALFFTNWKHEQ-LJQANCHMSA-N 0.000 description 1
- XPLYEWXKAIMIBA-LJQANCHMSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=CC=C2C=C(N(CC3CC3)C2=N1)C1=NC2=CC(=CC=C2N1C)C(=O)N1CCC[C@@H](N)C1 XPLYEWXKAIMIBA-LJQANCHMSA-N 0.000 description 1
- FJPMLKYYLXRBCH-HXUWFJFHSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-ethyl-7-methoxybenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CC)C(=CC(=C2)C(=O)N1C[C@@H](CCC1)N)OC FJPMLKYYLXRBCH-HXUWFJFHSA-N 0.000 description 1
- BPUSOYWBQOWXMQ-LJQANCHMSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methyl-7-methylsulfonylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@@H](CCC1)N)S(=O)(=O)C BPUSOYWBQOWXMQ-LJQANCHMSA-N 0.000 description 1
- IXTAPXWNZWLCFI-HXUWFJFHSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-(hydroxymethyl)-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC2)C)C(=C1)CO IXTAPXWNZWLCFI-HXUWFJFHSA-N 0.000 description 1
- TWVXVVCENBEGLS-OXQOHEQNSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-[(1R)-1-cyclopropylethyl]pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=C2N(C)C(=NC2=CC(=C1)C(=O)N1CCC[C@@H](N)C1)C1=CC2=CC=CN=C2N1[C@H](C)C1CC1 TWVXVVCENBEGLS-OXQOHEQNSA-N 0.000 description 1
- TWVXVVCENBEGLS-OXJNMPFZSA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-[(1S)-1-cyclopropylethyl]pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=C2N(C)C(=NC2=CC(=C1)C(=O)N1CCC[C@@H](N)C1)C1=CC2=CC=CN=C2N1[C@@H](C)C1CC1 TWVXVVCENBEGLS-OXJNMPFZSA-N 0.000 description 1
- VURFVYXBMIJKBU-APFDBTJISA-N [(3R)-3-aminopiperidin-1-yl]-[2-[1-[(3-hydroxy-3-methylcyclobutyl)methyl]pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound N[C@H]1CN(CCC1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2CC(C2)(O)C)C)C=C1 VURFVYXBMIJKBU-APFDBTJISA-N 0.000 description 1
- YHFWUKDGIOFJKV-XXBNENTESA-N [(3R,4S)-3-amino-4-methoxypiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C=CC(=C2)C(=O)N1C[C@H]([C@H](CC1)OC)N YHFWUKDGIOFJKV-XXBNENTESA-N 0.000 description 1
- WDBVVRWXLZICQV-QZTJIDSGSA-N [(3R,5R)-3-amino-5-fluoropiperidin-1-yl]-[2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-7-(difluoromethoxy)-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1C[C@@H](C[C@H](C1)F)N)OC(F)F WDBVVRWXLZICQV-QZTJIDSGSA-N 0.000 description 1
- YHFWUKDGIOFJKV-WMZHIEFXSA-N [(3S,4R)-3-amino-4-methoxypiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C=CC(=C2)C(=O)N1C[C@@H]([C@@H](CC1)OC)N YHFWUKDGIOFJKV-WMZHIEFXSA-N 0.000 description 1
- VOCFOFISMKUSCU-OALUTQOASA-N [(3S,5S)-3-amino-5-fluoropiperidin-1-yl]-[7-methoxy-1-methyl-2-[1-[(1-methylcyclopropyl)methyl]pyrrolo[2,3-b]pyridin-2-yl]benzimidazol-5-yl]methanone Chemical compound F[C@H]1C[C@@H](CN(C1)C(=O)C1=CC2=C(N(C(=N2)C2=CC=3C(=NC=CC=3)N2CC2(CC2)C)C)C(=C1)OC)N VOCFOFISMKUSCU-OALUTQOASA-N 0.000 description 1
- PELLZROKXXBRFB-BWKNWUBXSA-N [(3aR,7aR)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-[1-(cyclopropylmethyl)-5-phenylpyrrol-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound N1CC[C@H]2[C@@H]1CN(CC2)C(=O)C1=CC2=C(N(C(=N2)C=2N(C(=CC=2)C2=CC=CC=C2)CC2CC2)C)C=C1 PELLZROKXXBRFB-BWKNWUBXSA-N 0.000 description 1
- MBJYGYANNLFRAN-UTKZUKDTSA-N [(3aR,7aR)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-[7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound COC1=C2N(C)C(=NC2=CC(=C1)C(=O)N1CC[C@H]2CCN[C@H]2C1)C1=CC2=C(N=CN=C2)N1CC1CC1 MBJYGYANNLFRAN-UTKZUKDTSA-N 0.000 description 1
- PELLZROKXXBRFB-SQJMNOBHSA-N [(3aS,7aS)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-[1-(cyclopropylmethyl)-5-phenylpyrrol-2-yl]-1-methylbenzimidazol-5-yl]methanone Chemical compound N1CC[C@@H]2[C@H]1CN(CC2)C(=O)C1=CC2=C(N(C(=N2)C=2N(C(=CC=2)C2=CC=CC=C2)CC2CC2)C)C=C1 PELLZROKXXBRFB-SQJMNOBHSA-N 0.000 description 1
- MBJYGYANNLFRAN-LAUBAEHRSA-N [(3aS,7aS)-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl]-[2-[7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone Chemical compound N1CC[C@@H]2[C@H]1CN(CC2)C(=O)C1=CC2=C(N(C(=N2)C2=CC3=C(N=CN=C3)N2CC2CC2)C)C(=C1)OC MBJYGYANNLFRAN-LAUBAEHRSA-N 0.000 description 1
- AAUOXFPKZLFRBY-FXDKQOQWSA-N [(7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone hydrochloride Chemical compound Cl.COc1cc(cc2nc(-c3cc4cccnc4n3CC3CC3)n(C)c12)C(=O)N1CC2CCC1[C@@H]2N AAUOXFPKZLFRBY-FXDKQOQWSA-N 0.000 description 1
- BBNQFBHQOPZKTI-AATRIKPKSA-N [(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=C(C(F)(F)F)C=C1 BBNQFBHQOPZKTI-AATRIKPKSA-N 0.000 description 1
- BYDWIEKBSJJKCP-UHFFFAOYSA-N [2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]-(4-fluoro-3-hydroxypiperidin-1-yl)methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(C(CC1)F)O)OC BYDWIEKBSJJKCP-UHFFFAOYSA-N 0.000 description 1
- FTBHIJUHWUYOOP-AAUAJYIVSA-N [2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]-[(1R,4R,6S,7R)-6,7-diamino-2-azabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2[C@H](C[C@H](C1)[C@H]2N)N)OC FTBHIJUHWUYOOP-AAUAJYIVSA-N 0.000 description 1
- KWVLYKULSRDHIG-OPJGWUQDSA-N [2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]-[(1R,4R,7R)-7-(dimethylamino)-2-azabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2N(C)C)OC KWVLYKULSRDHIG-OPJGWUQDSA-N 0.000 description 1
- PAQRJFFVJLGBFG-MEKIYTOJSA-N [2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]-[(1R,4R,7R)-7-(methylamino)-2-azabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1[C@@H]2CC[C@H](C1)[C@H]2NC)OC PAQRJFFVJLGBFG-MEKIYTOJSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000006217 arginine-methylation Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- ZOHDMZDTYNCUBC-LSDHHAIUSA-N benzyl (3s,4r)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound C1C[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)CN1C(=O)OCC1=CC=CC=C1 ZOHDMZDTYNCUBC-LSDHHAIUSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- IQNNFQCFIONPHV-UHFFFAOYSA-N cyclopropylmethyl 2-chloro-7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound ClC=1N=CC2=C(N=1)N(C(=C2)C(=O)OCC1CC1)CC1CC1 IQNNFQCFIONPHV-UHFFFAOYSA-N 0.000 description 1
- RJCUEVMJKBIMAH-UHFFFAOYSA-N cyclopropylmethyl 7-(cyclopropylmethyl)-2-methoxypyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound C1(CC1)CN1C(=CC2=C1N=C(N=C2)OC)C(=O)OCC1CC1 RJCUEVMJKBIMAH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical group CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PTXJGGGNGMPMBG-UHFFFAOYSA-N ditert-butyl-[2-(1,3,5-triphenylpyrazol-4-yl)pyrazol-3-yl]phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=NN1C1=C(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 PTXJGGGNGMPMBG-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical class CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- AIDNMBYCKNLFMH-UHFFFAOYSA-N ethyl 1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C(=O)OCC AIDNMBYCKNLFMH-UHFFFAOYSA-N 0.000 description 1
- VDNAJGRMUOLRRW-UHFFFAOYSA-N ethyl 1-[(3-hydroxy-3-methylcyclobutyl)methyl]pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound OC1(CC(C1)CN1C(=CC=2C1=NC=CC=2)C(=O)OCC)C VDNAJGRMUOLRRW-UHFFFAOYSA-N 0.000 description 1
- UUYJISACTSPBQY-UHFFFAOYSA-N ethyl 6-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound ClC1=CC=C2C(=N1)N(C(=C2)C(=O)OCC)CC1CC1 UUYJISACTSPBQY-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical class CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007820 inflammatory cell apoptotic process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WWXBDQHEKVRUQJ-UHFFFAOYSA-N methyl 1-(cyclopropylmethyl)-6-oxo-7H-pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)O)C(=O)OC WWXBDQHEKVRUQJ-UHFFFAOYSA-N 0.000 description 1
- LACWWHAFCWGGGS-UHFFFAOYSA-N methyl 1-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carbonyl]-5-hydroxypiperidine-3-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)N1CC(CC(C1)O)C(=O)OC)OC LACWWHAFCWGGGS-UHFFFAOYSA-N 0.000 description 1
- LGFVHMWCAOXOSU-UHFFFAOYSA-N methyl 2-(1-ethyl-6-formylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound C(C)N1C(=CC=2C1=NC(=CC=2)C=O)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC LGFVHMWCAOXOSU-UHFFFAOYSA-N 0.000 description 1
- ULCGTJAGRBHSFX-UHFFFAOYSA-N methyl 2-(6-ethenyl-1-ethylpyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound C(=C)C1=CC=C2C(=N1)N(C(=C2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC)CC ULCGTJAGRBHSFX-UHFFFAOYSA-N 0.000 description 1
- KLUZHTMZPJCNJK-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)-6-ethylpyrrolo[2,3-b]pyridin-2-yl]-1-ethyl-7-methoxybenzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)CC)C1=NC2=C(N1CC)C(=CC(=C2)C(=O)OC)OC KLUZHTMZPJCNJK-UHFFFAOYSA-N 0.000 description 1
- DHRWCXWXGXTFOB-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-1-methylbenzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1C)C=CC(=C2)C(=O)OC DHRWCXWXGXTFOB-UHFFFAOYSA-N 0.000 description 1
- UWGAHVNSEPQPTC-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)-6-methoxypyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC(=CC=2)OC)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC UWGAHVNSEPQPTC-UHFFFAOYSA-N 0.000 description 1
- HCYUIUUZBVVUIW-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-(difluoromethoxy)-1-methylbenzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC(F)F HCYUIUUZBVVUIW-UHFFFAOYSA-N 0.000 description 1
- TWSUFNYCJMIJOR-UHFFFAOYSA-N methyl 2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-(2-methylsulfanylethyl)benzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC=2C1=NC=CC=2)C1=NC2=C(N1CCSC)C(=CC(=C2)C(=O)OC)OC TWSUFNYCJMIJOR-UHFFFAOYSA-N 0.000 description 1
- IAMSYOWYWOSKCU-UHFFFAOYSA-N methyl 2-[2-chloro-7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound ClC=1N=CC2=C(N=1)N(C(=C2)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC)CC1CC1 IAMSYOWYWOSKCU-UHFFFAOYSA-N 0.000 description 1
- HOJJJKFLCADLDF-UHFFFAOYSA-N methyl 2-[6-(difluoromethyl)-1-ethylpyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound CCN1C(=CC2=CC=C(N=C12)C(F)F)C1=NC2=CC(=CC(OC)=C2N1C)C(=O)OC HOJJJKFLCADLDF-UHFFFAOYSA-N 0.000 description 1
- FKUUBDNUYRKTJY-UHFFFAOYSA-N methyl 2-[6-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-1-ethyl-7-methoxybenzimidazole-5-carboxylate Chemical compound CCN1C(=NC2=CC(=CC(OC)=C12)C(=O)OC)C1=CC2=C(N=C(Cl)C=C2)N1CC1CC1 FKUUBDNUYRKTJY-UHFFFAOYSA-N 0.000 description 1
- AQLNPQHILFHGFB-UHFFFAOYSA-N methyl 2-[7-(cyclopropylmethyl)-2-methylpyrrolo[2,3-d]pyrimidin-6-yl]-7-methoxy-1-methylbenzimidazole-5-carboxylate Chemical compound C1(CC1)CN1C(=CC2=C1N=C(N=C2)C)C1=NC2=C(N1C)C(=CC(=C2)C(=O)OC)OC AQLNPQHILFHGFB-UHFFFAOYSA-N 0.000 description 1
- YRANLORKRAYAFN-UHFFFAOYSA-N methyl 2-chloro-7-(cyclopropylmethyl)pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound ClC=1N=CC2=C(N=1)N(C(=C2)C(=O)OC)CC1CC1 YRANLORKRAYAFN-UHFFFAOYSA-N 0.000 description 1
- UMFBBZSEFIBVJL-UHFFFAOYSA-N methyl 2-chloro-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound ClC=1N=CC2=C(N=1)NC(=C2)C(=O)OC UMFBBZSEFIBVJL-UHFFFAOYSA-N 0.000 description 1
- SPSVQVKAYOHSBJ-UHFFFAOYSA-N methyl 4-chloro-2-methoxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(Cl)C=C1OC SPSVQVKAYOHSBJ-UHFFFAOYSA-N 0.000 description 1
- JUCFNZJKUATDQS-UHFFFAOYSA-N methyl 4-fluoro-2-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1C JUCFNZJKUATDQS-UHFFFAOYSA-N 0.000 description 1
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 1
- LJYSUEZSIXOJFK-UHFFFAOYSA-N methyl 5-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(N)C=N1 LJYSUEZSIXOJFK-UHFFFAOYSA-N 0.000 description 1
- OCJVBOGOCYXQQM-UHFFFAOYSA-N methyl 6-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound ClC1=CC=C2C(=N1)N(C(=C2)C(=O)OC)CC1CC1 OCJVBOGOCYXQQM-UHFFFAOYSA-N 0.000 description 1
- MPZMZNBDKQBVIV-UHFFFAOYSA-N methyl 7h-pyrrolo[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=CN=C2NC(C(=O)OC)=CC2=C1 MPZMZNBDKQBVIV-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical class C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229940038031 nitrogen 10 % Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- GSWAOPJLTADLTN-UHFFFAOYSA-N oxidanimine Chemical compound [O-][NH3+] GSWAOPJLTADLTN-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IZVUMRPAZPCMTK-HTQZYQBOSA-N tert-butyl (3r,5r)-3-amino-5-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](N)C[C@@H](O)C1 IZVUMRPAZPCMTK-HTQZYQBOSA-N 0.000 description 1
- YWAJEBAYQRUZQD-UHFFFAOYSA-N tert-butyl 4-chloro-1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridine-2-carboxylate Chemical compound ClC1=C2C(=NC=C1)N(C(=C2)C(=O)OC(C)(C)C)CC1CC1 YWAJEBAYQRUZQD-UHFFFAOYSA-N 0.000 description 1
- LKMTYLUKCLIYBU-UHFFFAOYSA-N tert-butyl n-(3-azabicyclo[2.2.1]heptan-7-yl)carbamate Chemical compound C1CC2NCC1C2NC(=O)OC(C)(C)C LKMTYLUKCLIYBU-UHFFFAOYSA-N 0.000 description 1
- NNMBHCRWGGSRBE-DTWKUNHWSA-N tert-butyl n-[(3r,6s)-6-methylpiperidin-3-yl]carbamate Chemical compound C[C@H]1CC[C@@H](NC(=O)OC(C)(C)C)CN1 NNMBHCRWGGSRBE-DTWKUNHWSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- GTDKXDWWMOMSFL-UHFFFAOYSA-M tetramethylazanium;fluoride Chemical compound [F-].C[N+](C)(C)C GTDKXDWWMOMSFL-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Chemical group 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
PAD4は、ペプチド配列内においてアルギニンをシトルリンへとシトルリン化を触媒作用することが可能なペプチジルアルギニンデイミナーゼ(PAD:peptidylarginine deiminase)ファミリーの酵素のメンバーである。PAD4は、様々な疾患において多様な機能性応答を結果として生じる生体外及び生体内における様々なタンパク質の脱イミン化又はシトルリン化に関与している(Jones J.E.ら, Curr. Opin. Drug Discov. Devel., 12(5), (2009), 616-627)。例示的な疾患の例には、腫瘍学的適応症の他に、関節リウマチ、病因に好中球が関与している疾患(例えば、血管炎、全身性エリテマトーデス、潰瘍性大腸炎)が含まれる。PAD4阻害剤は、ヒトの後成的(epigenetic)機序による疾患へのツール及び治療法としてより広い適用性を有することもできる。
式Iの化合物:
(式中、環A、R1、R2、R3、R4、X1およびX2の各々は、本明細書において規定されたとおり)
あるいはその医薬的に許容される塩は、PAD4の阻害剤として有用であることを見出した。
(式中、環A、環B、R1およびR3の各々は、本明細書に規定されたとおりである)
あるいはその医薬的に許容される塩は、PAD4の阻害剤として有用であることも見出された。
1.本発明の幾つかの態様の一般的な記述
ある実施態様において、前記化合物は、本明細書において記述された製剤あるいはその医薬的に許容される塩であって、式中の各可変部は、本明細書において規定かつ実施態様に記述されたとおりである。本願化合物は、式I:
環Aは、
であって、ここで環Aは、フッ素、−CN、−ORまたはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)から選択される1〜4つの基で所望により置換されていてもよい;
R1は、水素、−CN、−ORまたはC1−6脂肪族基(フッ素、−CNまたはORから選択された1〜4つの基で所望により置換されていてもよい)であり;
R2は、水素であるか、あるいはフッ素、−CNまたは−ORから選択される1〜5つの基で所望により置換されていてもよいC1−10脂肪族基であり;
X1およびX2の各々は、独立して、NまたはC(R4)から選択され;
R3およびR4の各々は、独立して、ハロゲン、−CN、−Rまたは−ORであり;
nは0〜4であり;および
各Rは、独立して、水素であるか、あるいは1〜3個のフッ素原子で所望により置換されていてもよいC1−6脂肪族基である]
の構造を有する化合物あるいはその医薬的に許容される塩を有する。
環Aは、
であって、環Aは、フッ素、−CN、−ORまたはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)から選択される1〜4つの基で所望により置換されていてもよい;
環Bは、
であり;
R1は、水素、−CN、−OR、
またはC1−6脂肪族基(フッ素、−CNまたは−ORから選択される1〜4つの基で所望により置換されていてもよい)であり;
R2は、水素であるか、あるいはフッ素、−CNまたは−ORから選択される1〜5つの基で所望により置換されていてもよいC1−10脂肪族基であり;
X1およびX2の各々は、独立して、NまたはC(R4)から選択され;
R3は、ハロゲン、−CN、−R、
または−ORであり;
各R4は、独立して、ハロゲン、−CN、−R、
または−ORであり;
R5は、水素またはハロゲンであり;
nは、0〜4であり;および
各Rは、独立して、水素であるか、あるいは1〜3個のフッ素原子で所望により置換されていてもよいC1−6脂肪族基である]
の構造を有する化合物あるいはその医薬的に許容される塩を有している。
本発明の化合物は、本明細書に概説されるものを含み、本明細書に記載の分類、下位分類および種類によりさらに説明される。特に明記されていない限り、本明細書に用いられる以下の定義が適用される。本発明のために、化学元素は、Handbook of Chemistry and Physics, 75th Edの元素周期表, CAS版にしたがって特定される。さらに、有機化学の一般的原理は、“Organic Chemistry”, Thomas Sorrell,University Science Books, Sausalito:1999, and “March's Advanced Organic Chemistry”, 5th Ed.,Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001に記載されており、その全内容は本明細書によって引用される。
一態様に従って、本発明は、式I:
環Aは、
であって、環Aは、フッ素、−CN、−ORまたはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)から選択される1〜4つの基で所望により置換されていてもよい;
R1は、水素、−CN、−ORまたはC1−6脂肪族基(フッ素、−CNまたは−ORから選択される1〜4つの基で所望により置換されていてもよい)であり;
R2は、水素またはC1−10脂肪族基(フッ素、−CNまたは−ORから選択される1〜5つの基で所望により置換されていてもよい)であり;
X1およびX2の各々は、独立して、NまたはC(R4)から選択され;
R3およびR4の各々は、独立して、ハロゲン、−CN、−Rまたは−ORであり;
nは0〜4である;および
各Rは、独立して、水素であるか、あるいはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)である]
の化合物あるいはその医薬的に許容される塩を提供する。
であり、環Aは、フッ素、−CN、−ORまたはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)から選択される1〜4つの基で所望により置換されていてもよい;
環Bは、
であり;
R1は、水素、−CN、−OR、
あるいはC1−6脂肪族基(フッ素、−CNまたは−ORから選択される1〜4つの基で所望により置換されていてもよい)であり;
R2は、フッ素、−CNまたは−ORから選択される1〜5つの基で所望により置換されていてもよいC1−10脂肪族基であり;
X1およびX2の各々は、独立して、NまたはC(R4)から選択され;
R3は、ハロゲン、−CN、−R
または−ORであり;
各R4は、独立して、ハロゲン、−CN、−R、
または−ORであり;
R5は、水素またはハロゲンであり;
nは0〜4であり;および
各Rは、独立して、水素またはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)である]
の化合物あるいはその医薬的に許容される塩を提供する。
である。ある実施態様において、R1は
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。
ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、
である。ある実施態様において、R1は、以下の表1に記載されたものから選択される。
である。ある実施態様において、R3は、
である。ある実施態様において、R3は、
である。ある実施態様において、R3は、以下の表1に記載されたものから選択される。
または−ORである。
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、
である。ある実施態様において、R4は、以下の表1に記載されたものから選択される。
であり、ここで環Aは、フッ素または1〜3個のフッ素原子で所望により置換されていてもよいC1−6脂肪族基から選択される1〜4つの基で所望により置換されていてもよい。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、
である。ある実施態様において、環Aは、以下の表1に記載されたものから選択される。
である。ある実施態様において、環Bは、
である。ある実施態様において、環Bは、
である。ある実施態様において、環Bは、
である。ある実施態様において、環Bは、
である。ある実施態様において、環Bは、以下の表1に記載されたものから選択される。
である。ある実施態様において、R1はメチルであり、R2は2,2,2−トリフルオロエチルであり、X1はNであり、X2はCHであり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はNであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はエチルであり、X1はNであり、X2はCHであり、R3は水素であり、環Aは、
ある。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はNであり、R3は水素であり、環Aは
である。ある実施態様において、R1はメチルであり、R2は2,2,2−トリフルオロエチルであり、X1はNであり、X2はCHであり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はNであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2は2,2,2−トリフルオロエチルであり、X1はNであり、X2はCHであり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はNであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はエチルであり、X1はNであり、X2はCHであり、R3は水素であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、R1はメチルであり、R2はシクロプロピルメチルであり、X1はNであり、X2はCHであり、R3は−OCH3であり、環Aは、
である。ある実施態様において、環Aは、
である。
別の実施態様によれば、本発明は、本発明の化合物またはその医薬的に許容される誘導体および医薬的に許容される担体、アジュバントまたはビヒクルを含む組成物を提供する。本発明の組成物中の化合物の量は、生物試料または患者において、PAD4を測定可能な程度に阻害するのに有効な量である。ある実施態様において、本発明の組成物は、該組成物を必要とする患者に投与するために処方される。ある実施態様において、本発明の組成物は、患者に経口投与するために処方される。
本明細書に記述した化合物および組成物は、一般的に、PAD4の阻害のために有用である。
以下の実施例において示したとおり、ある実施態様の例示において、化合物を以下の一般方法に従って製造した。一般方法は、本発明のある特定の化合物の合成を表しているが、以下の一般方法および当業者には既知の別法が、本明細書に記載したような全ての化合物およびこれらの各化合物のサブクラスおよび系統に適用され得ることは理解されよう。
MET/u−HPLC(低pH 7分 方法)
カラム:Phenomenex Kinetex−XB C18, 2.1mm x 100mm, 1.7μm
流量:0.6ml/分
移動相:
A:ギ酸(水溶液)0.1%およびB:ギ酸(MeCN)0.1%
インジェクション量:3μl
温度;40℃
検出:215nm(ノミナル)
グラジエント時間(分)−%B
0.00〜5
5.30〜100
5.80〜100
5.82〜5
MET/CR/1600(高pH 7分 方法)
カラム:Phenomenex Gemini C18, 2.0mm x 100mm,3μm
流量:0.5ml/分
移動相:
A:2mM 炭酸水素アンモニウム塩/HPLC等級の水 pH10
B:HPLC等級MeCN
インジェクション量:3μl
温度:50℃
検出:215nm
グラジエント時間:(分)−%B
1.0〜5
5.50〜100
5.90〜100
5.92〜5
9.00〜5
METCR 1416(低pH Shimadzu 7分 方法)
カラム:Waters Atlantis dC18,2.1mm x 100mm,3μmカラム
流量:0.6ml/分
移動相:
A:ギ酸(水溶液)0.1%、およびB:ギ酸(アセトニトリル)0.1%
インジェクション量:3μl
温度;40℃
検出:215nm(ノミナル)
グラジエント時間(分)−%B
0.00〜5
5.00〜100
5.40〜100
5.42−5
METCR 1410(低pH Shimadzu 2分 方法)
カラム:Kinete x Core-Shell C18, 2.1mm x 50mm,5μmカラム
流量:1.2ml/分
移動相:
A:ギ酸(水溶液)0.1%、およびB:ギ酸(アセトニトリル)0.1%
インジェクション量:3μl
温度;40℃
検出:215nm(ノミナル)
グラジエント時間(分)−%B
0.00〜5
1.20〜100
1.30〜100
1.31−5
キラルHPLC分取方法
カラム:Chiralpak IC 250mm x 4.6mm,5μmカラム
流量:15ml/分
移動相:35% エタノール:65%CO2
試料希釈剤:エタノール
温度;40℃
検出:215nm(ノミナル)
キラ純度分析方法
カラム:Chiralpak IC 250mm x 4.6mm,5μmカラム
流量:4ml/分
インジェクション量:10μL
温度;40℃
検出:215nm
アイソクラティック条件 40% エタノール:60%CO2
キラルHPLC分取方法
カラム:XSelect CSH C18 50 x 2.1 mm, 1.7um
流量:0.6ml/分
移動相:水(0.1%v/v TFA)、MecN(0.1%v/v TFA)
試料希釈剤:エタノール
温度;40℃
検出:240nm(ノミナル)
MET/u−HPLC(高pH MS16 7分 方法)
カラム:Waters UPLC CSH C18, 2.1 mm x 100mm 5μmカラム
流量:0.6ml/分
移動相:
A:2mM pH10に調整した炭酸水素アンモニウム塩(水酸化アンモニウム(水溶液)を含む)、および
B:アセトニトリル
インジェクション量:3μl
温度;40℃
検出:215nm(ノミナル)
グラジエント時間(分)−%B
0.00〜5
5.30〜100
5.80〜100
5.82〜5
キラ純度分析方法
カラム:Lux C4 (21.2mm x 250mm, 5um)
流量:21ml/分
インジェクション量:350μL
検出:222nm
アイソクラティック条件:MeOH(0.1%v/vNH3)
MET/CR/0990(高pH 3分 方法)
カラム:Phenomenex Gemini C18, 2.0mm x 100mm,3μm
流量:1ml/分
移動相:
A:2mM 炭酸水素アンモニウム塩/HPLC等級の水 pH10
B:HPLC等級のMeCN
インジェクション量:3μl
温度:60℃
検出:215nm
グラジエント時間:(分)−%B
0.0〜1
1.80〜100
2.10〜100
2.30〜1
キラルHPLC分取方法
カラム:Amy-C 20mm x 250mm, 5um
流量:21ml/分
移動相:
4:6 ヘプタン:エタノール(0.1%v/v アンモニア)
試料希釈剤:メタノール
温度;周囲温度
検出:254nm
キラ純度分析方法
カラム:Amy-C 4.6mm x 250mm, 5um
流量:21ml/分
インジェクション量:1.0μL
温度;周囲温度
UV検出:254nm
アイソクラティック条件である4:6 ヘプタン:エタノール(0.1%v/v アンモニア)
メチル 4−クロロ−3−メトキシ−5−ニトロベンゾエート(CAS63603−09−8,2.0g,8.14mmol)/DMF(10ml)の攪拌溶液に、K2CO3(99%,1.37g,9.81mmol)を加えた。この溶液に、メタンアミン塩酸塩(1:1)(0.62g,9.18mmol)を加えて、混合物を、窒素下において、80℃で16時間、密封管内で攪拌した。反応粗生物を、真空濃縮して、DCM(100ml)および水(10ml)との層間に分配した。有機層を、水(2x10ml)および飽和塩化ナトリウム水溶液(10ml)でさらに洗った。有機層を、硫酸ナトリウムで乾燥させて、濾過して、真空濃縮して、橙色の粉末を得て、これをフラッシュクロマトグラフィーにより精製して(15〜40% EtOAc/ヘプタン)、メチル 3−メトキシ−4−(メチルアミノ)−5−ニトロベンゾエート EV−AR0065−002[1.49g(76%)]を橙色の粉末として得た。LCMS(方法D):保持時間1.13分間,M/z=241−(M+1).
メチル 3−メトキシ−4−(メチルアミノ)−5−ニトロベンゾエート(EV−AR0065−002,1.49g,6.20mmol)/エタノール(100ml)の攪拌溶液に、窒素下にて、10% Pd/C(0.18g,0.17mmol)を加えて、得られる混合物を、室温で16時間、水素雰囲気下で攪拌した。反応混合物を、Kieselguhrを通して濾過して、濾液をメタノール(150ml)を通して洗った。濾液を、真空で濃縮して、メチル 3−アミノ−5−メトキシ−4−(メチルアミノ)ベンゾエート EV−AR0068−002[1.21g(89%)]を淡紫色の粉体として得た。LCMS(方法D):保持時間0.63分間,M/z=211−(M+1).
水素化ナトリウム(60%,59mg,1.47mmol)を、数回に分けて滴加して、室温で、エチル1H−ピロロ[2,3−b]ピリジン−2−カルボキシレート(CAS221675−35−0,200mg,1.05mmol)/DMF(5ml)の懸濁液に加えた。混合物を、20分間攪拌して、次いでヨウ化エチル(197mg,1.26mmol)を加えた。反応混合物を20時間攪拌した。混合物を、EtOAc(20ml)および水(20ml)の層間に分配した。水層を、EtOAc(1x20ml)で更に抽出して、合わせた有機層を水(20ml)で洗い、蒸発乾固させた。粗生成物を、フラッシュクロマトグラフィーにより精製して(0〜50% EtOAc/ヘプタン)、エチル 1−エチル−1H−ピロロ[2,3−b]ピリジン−2−カルボキシレート EV−AQ1957−001[135mg(57.1%)]を無色油状物として得た。LCMS(方法D):保持時間1.18分間,M/z=219(M+1).
1−エチル−1H−ピロロ[2,3−b]ピリジン−2−カルボン酸(EV−AQ1960−001,120mg,0.63mmol)/DMF(2ml)の攪拌溶液に、DIPEA(116μl,0.70mmol)、次いでHATU(236mg,0.62mmol)を加えて、得られる混合物を、室温で15分間攪拌した。メチル 3−アミノ−5−メトキシ−4−(メチルアミノ)ベンゾエート(EV−AR0068−002,148mg,0.70mmol)を加えて、得られる混合物を、室温で6時間攪拌した。反応混合物を、真空濃縮して、酢酸(3ml)に溶解して、70℃で16時間攪拌した。溶媒を、真空除去して、フラッシュクロマトグラフィーにより精製して(25〜40% EtOAc/ヘプタン)、メチル 2−{1−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル}−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボキシレートEV−AR0070−003[150mg(63%)]を白色粉末として得た。LCMS(方法D):保持時間1.18分間,M/z=365(M+1).
メチル 2−{1−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル}−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボキシレート(EV−AR0070−003,150mg,0.41mmol)/THF(3ml)の攪拌溶液に、水酸化リチウム(30mg,1.25mmol)/水(3ml)の溶液を加えて、混合物を室温で16時間攪拌した。反応混合物を、真空濃縮して、水(5ml)に取り、攪拌しながら5N HCl(0.5ml)を用いて酸性化した。得られる懸濁液を、10分間攪拌して、次いで沈殿物を、真空濾過により回収して、乾燥させて、2−{1−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル}−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボン酸 EV−AR0072−002[130mg(89%)]を白色粉末として得た。LCMS(方法D):保持時間1.03分間,M/z=351−(M+1).
EV−AR0090−001,キラル純度(UV,254nm):100%,保持時間:6.30分(方法F)
EV−AR0090−002,キラル純度(UV,254nm):97%,保持時間:9.96分(方法F)
Tert−ブチル(3aR,7aS)−6−(2−{1−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル}−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボニル)−オクタヒドロ−1H−ピロロ[2,3−c]ピリジン−1−カルボキシレート(EV−AR0090−001,46mg,0.08mmol)を、工程8,スキーム1の通りに処理して、5−[(3aS,7aS)−オクタヒドロ−1H−ピロロ[2,3−c]ピリジン−6−カルボニル]−2−{1−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル}−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール塩酸塩 EV−AR0091−002,I−3[40mg(97%)]を橙色の粉末として得た。LCMS(方法A):保持時間1.83分間,M/z=459(M+1).
エチル1H−ピロロ[2,3−b]ピリジン−2−カルボキシレート(CAS221675−35−0,4.40g,23.1mmol)/DMF(50ml)の攪拌溶液に、水素化ナトリウム(60%,1.05g,26.3mmol)を加えた。混合物を、窒素下において、室温で45分間攪拌して、(ブロモメチル)シクロプロパン(CAS7051−34−5,2.70ml,27.8mmol)を加えた。混合物を、室温で2.5時間攪拌して、溶媒を真空除去した。残留物を、THF(40ml)に懸濁して、5M 水酸化ナトリウム水溶液(22ml,110mmol)を加えた。混合物を、50℃で3.5時間攪拌した。追加のTHF(20ml)および5M 水酸化ナトリウム水溶液(22ml,110mmol)を加えて、この反応を50℃で16時間攪拌した。反応粗生成物を、真空濃縮して、水(10ml)および5M 塩酸水溶液(100ml)を加えた。固体を濾取して、水(2x100ml)で洗い、真空オーブン内で乾燥させて、1−(シクロプロピルメチル)−1H−ピロロ[2,3−b]ピリジン−2−カルボン酸 EV−AR3164−001[3.46g(69.2%)]を白色粉末として得た。LCMS(方法D):保持時間1.03分間,M/z=217(M+1).
メチル 4−フルオロ−3−ニトロベンゾエート(CAS329−59−9,5.00g,25.1mmol)/DMF(50ml)の攪拌溶液に、メタンアミン塩酸塩(1:1)(2.00g,29.6mmol)および炭酸カリウム(4.50g,32.6mmol)を加えた。混合物を、窒素下にて、室温で18時間攪拌した。反応の粗生成物を、真空濃縮して、残留物を、EtOAc(350ml)および1N 塩酸水溶液(250ml)の層間に分配した。有機層を、1N 塩酸水溶液(150ml)および飽和塩化ナトリウム水溶液(100ml)を用いて更に洗った。有機層を、硫酸マグネシウムで乾燥させて、濾過して、真空濃縮して、メチル 4−(メチルアミノ)−3−ニトロベンゾエートEV−AR3152−001[5.30g(定量的)]を、黄色粉末として得た。LCMS(方法D):保持時間1.07分間,M/z=211−(M+1).
メチル 4−(メチルアミノ)−3−ニトロベンゾエート(EV−AR3152−001,5.30g,25.2mmol)/エタノール(100ml)の攪拌溶液に、窒素下において、10% Pd/C(1.30g,0.05mmol)を加えた。次いで、反応を、水素雰囲気下にて、室温で4時間攪拌した。反応混合物を、メタノール(100ml)で希釈して、Kieselguhrを加えた。混合物を、室温で10分間攪拌して、真空濾過した。濾液を、メタノール(3x50ml)で洗い、濾液を真空濃縮して、メチル 3−アミノ−4−(メチルアミノ)ベンゾエート EV−AR3155−001[4.39g(96.6%)]を褐色粉末として得た。LCMS(方法D):保持時間0.75分間,M/z=181−(M+1).
EV−AS1581−003キラル純度(UV,254nm):100%,保持時間:10.07分(方法L)
5−フェニル−1H−ピロール−2−カルボン酸(CAS6636−06−2,500mg,2.67mmol)/トルエン(10ml)およびメタノール(3ml)の攪拌溶液に、2M(ジアゾメチル)(トリメチル)シラン/ヘキサン(2ml)を加えて、混合物を、窒素下にて、室温で30分間攪拌した。反応混合物に、酢酸(1ml)を加えて、混合物を真空濃縮して、メチル 5−フェニル−1H−ピロール−2−カルボキシレート(EV−AR0054−002)[530mg(99%)]を淡黄色粉末として得た。LCMS(方法D):保持時間1.14分間,M/z=202(M+1).
3−ヒドロキシ−3−メチルシクロブタンカルボン酸(CAS16286−86−5,950mg,7.30mmol)/THF(30ml)の攪拌溶液に、BH3・Me2S(4.96ml,9.93mmol)を−78℃で滴加した。反応溶液を、室温に昇温させて、16時間攪拌した。反応溶液を、無水MeOH(20ml)でクエンチした。得られる混合物を、減圧乾燥させて、3−(ヒドロキシメチル)−1−メチルシクロブタン−1−オール EV−AU7264−001[200mg(23.2%)]を無色油状物として得た。
Tert−ブチル N−[(3R)−1−{2−[1−(シクロプロピルメチル)−4−[(ジフェニルメチリデン)アミノ]−1H−ピロロ[2,3−b]ピリジン−2−イル]−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボニル}ピペリジン−3−イル]カルバメート EV−AT0090−001−工程1
EV−AR0090−002キラル純度(UV,254nm):97%,保持時間:9.96分(方法F)
スキーム3.1に記述したエチル 1−[(1−メチルシクロプロピル)メチル]−1H−ピロロ[2,3−b]ピリジン−2−カルボキシレート EV−AU3682−002の合成を介して、(3S,5S)−5−フルオロ−1−(7−メトキシ−1−メチル−2−{1−[(1−メチルシクロプロピル)メチル]−1H−ピロロ[2,3−b]ピリジン−2−イル}−1H−1,3−ベンゾジアゾール−5−カルボニル)ピペリジン−3−アミン EV−AV3056−001−(EOAI3454078)I−93を、スキーム2に記述した方法に従って合成した:
メチル 2−[6−クロロ−1−(シクロプロピルメチル)−1H−ピロロ[2,3−b]ピリジン−2−イル]−1−エチル−7−メトキシ−1H−1,3−ベンゾジアゾール−5−カルボキシレート EV−AV4831−001(スキーム2に従って合成した,150mg,0.31mmol)/無水THF(5ml)の溶液に、Fe(acac)3(6mg,0.02mmol)およびNMP(150μl)を加えた。エチルマグネシウムブロミド(THF中で0.9M,411μl,0.37mmol)の溶液を、1分かけて滴加して、反応混合物を、室温で3時間攪拌した。更なるFe(acac)3(6mg,0.02mmol)およびエチルマグネシウムブロミド(THF中で0.9M,411μl,0.37mmol)を加えて、反応混合物を、室温で16時間攪拌した。この反応を、1M HCl(〜1ml)の添加によりクエンチして、DCM(3x15ml)で抽出した。有機層を合わせて、塩水(20ml)で洗い、硫酸マグネシウムで乾燥させて、真空濃縮した。粗製残留物を、分取HPLCにより精製して(酸性の方法)、メチル 2−[1−(シクロプロピルメチル)−6−エチル−1H−ピロロ[2,3−b]ピリジン−2−イル]−1−エチル−7−メトキシ−1H−1,3−ベンゾジアゾール−5−カルボキシレート EV−AV4834−002[81mg(55%)]を無色のガラス状物として得た。LCMS(方法A):保持時間4.59分間,M/z=433(M+1).
注:出発物質および生成物はtrans−ラセミ体である。
EV−AW6273−002−工程2
rac−tert−ブチル N−[(3R,6S)−1−{2−[1−(シクロプロピルメチル)−1H−ピロロ[2,3−b]ピリジン−2−イル]−7−メトキシ−1−メチル−1H−1,3−ベンゾジアゾール−5−カルボニル}−6−(ヒドロキシメチル)ピペリジン−3−イル]カルバメート EV−AX4594−001[70mg(22%)]をオフホワイトの固体として得た。LCMS(方法D):保持時間1.18分間,M/z=589(M+1).
シクロプロピルメチル 2−クロロ−7−(シクロプロピルメチル)−7H−ピロロ[2,3−d]ピリミジン−6−カルボキシレート EV−AX5535−003[113mg(8%)]を、オフホワイトの粉末として得た。LCMS(方法D):保持時間1.38分間,M/z=306/308(M+1).
メチル 2−クロロ−7−(シクロプロピルメチル)−7H−ピロロ[2,3−d]ピリミジン−6−カルボキシレートEV−AX5535−004[256mg(20%)]を、オフホワイト結晶固体として得た。LCMS(方法D):1.24分間,M/z=266/268(M+1).
シクロプロピルメチル 7−(シクロプロピルメチル)−2−メトキシ−7H−ピロロ[2,3−d]ピリミジン−6−カルボキシレート EV−AX5535−005[93mg(6%)]を黄色ガム状物として得た。LCMS(方法D):保持時間1.32分間,M/z=302(M+1).
メチル 7−(シクロプロピルメチル)−2−メトキシ−7H−ピロロ[2,3−d]ピリミジン−6−カルボキシレート EV−AX5535−006[197mg(16%)]を、黄色結晶体として得た。LCMS(方法D):保持時間1.20分間,M/z=262(M+1).
6−クロロ−1−(シクロプロピルメチル)−1H−ピロロ[2,3−b]ピリジン−2−カルボン酸(EV−AU7974−001,500mg,1.99mmol)/トルエン(30ml)の攪拌した懸濁液を、85℃に加熱した後に、N,N−ジメチルホルムアミド ジ−tert−ブチルアセタール(2.0ml,8.34mmol)を滴加した。反応混合物を、85℃で2時間攪拌して、更にN,N−ジメチルホルムアミド ジ−tert−ブチルアセタール(2.0ml,8.34mmol)を加えた。攪拌を、85℃で18時間続けて、その後100℃で3時間攪拌した。冷却後に、反応混合物を、EtOAc(200ml)で希釈して、飽和塩化ナトリウム水溶液(50ml)で洗い、硫酸マグネシウムで乾燥させて、濾過して、真空濃縮した。粗生成物を、フラッシュクロマトグラフィーにより精製して(0〜10% EtOAc/ヘプタン)、tert−ブチル 6−クロロ−1−(シクロプロピルメチル)−1H−ピロロ[2,3−b]ピリジン−2−カルボキシレート EV−AX4139−005[366mg(60%)]を無色油状物として得た。LCMS(方法D):保持時間1.66分間,M/z=307/309(M+1).
EV−AV3033−003キラル純度(UV,254nm):100%,保持時間:7.87分(方法I)
LCMS(方法D):保持時間0.27分間,M/z=247(M+1).
1H NMR(500MHz,クロロホルム−d) δ 5.78−5.48(m,1H),3.94(d,J=7.6Hz,1H),3.49(d,J=6.1Hz,1H),3.34(s,3H),3.22(s,1H),2.99(d,J=9.2Hz,1H),2.47(d,J=9.5Hz,1H),2.41−(s,1H),1.90(dd, J=13.5,7.1Hz,1H),1.75−1.63(m,2H),1.44(s,9H).LCMSデータなし。
注:出発物質はシス−ラセミ体であった。
(カラム:Waters XBridge C18, 2.1mm x 50 mm, 1.7μm粒子;移動相A:5:95 アセトニトリル:水(0.1% トリフルオロ酢酸を含む);移動相B:95:5 アセトニトリル:水(0.1% トリフルオロ酢酸を含む);温度:50℃;グラジエント:3分かけて0%B〜100%B、次いで0.75分100%Bで保持;流量:1mL/分;検出:MSおよびUV(220nm)).M/Z(+)=487.12;塩=遊離塩基。
カラム:Waters Acquity SDS
移動相:
溶媒A:水
溶媒B:アセトニトリル
グラジエント範囲:
1分(“min”)かけて2%〜98%溶媒Bの直線のグラジエント、
98%Bで0.5分(“min”)保持。
グラジエント時間:1分
分析時間:1.7分
検出器:254ナノメーター(“nm”)での紫外線(“UV”)による可視化
スキーム11を用いて製造した。
1H NMR(500MHz,DMSO−d6)シフト 8.03−7.96(m,1H),7.80−7.70(m,2H),7.44−7.36(m,1H),7.06−7.02(m,1H),6.71−6.60(m,1H),4.56−4.36(m,2H),4.01−3.94(m,3H),3.94−3.89(m,3H),3.48−3.33(m,1H),3.07−2.87(m,1H),2.42−2.28(m,1H),1.93−1.72(m,1H),1.21−1.04(m,1H),0.35−0.24(m,2H),0.22−0.08(m,2H).
スキーム12に従って製造した。
1−(シクロプロピルメチル)−6−メトキシ−1H−ピロロ[2,3−b]ピリジン−2−カルボン酸(5g,20.30mmol)、HATU(7.72g,20.30mmol)およびDIPEA(10.64ml,60.9mmol)を、DMF(80ml)に加えた。反応溶液を、15分間室温で攪拌して、この時点でメチル 3−アミノ−5−メトキシ−4−(メチルアミノ)ベンゾエート,HCl塩(5.51g,22.33mmol)を加えて、反応溶液を終夜攪拌した。溶媒を、真空下に除去して、AcOH(120mL)を残留物に加えた。反応溶液を70℃で4時間攪拌して、次いでAcOHを真空除去して、粗生成物をセライト上で吸収させて、自動化クロマトグラフィーを用いて精製して、メチル 2−(1−(シクロプロピルメチル)−6−メトキシ−1H−ピロロ[2,3−b]ピリジン−2−イル)−7−メトキシ−1−メチル−1H−ベンゾ[d]イミダゾール−5−カルボキシレート(6.5g,15.46mmol,76%収率)を得た。LCMS:保持時間0.98分間,M/z=421.0(M+1).
1H NMR(500MHz,DMSO−d6)シフト 8.03−7.98(m,1H),7.28−7.22(m,1H),7.01−6.94(m,1H),6.83−6.77(m,1H),6.70−6.61−(m,1H),4.48−4.38(m,2H),4.17−4.06(m,3H),4.00−3.96(m,3H),3.96−3.93(m,3H),2.70−2.62(m,1H),2.56−2.52(m,3H),1.90−1.88(m,2H),1.76−1.62(m,2H),1.58−1.39(m,2H),1.26−1.12(m,4H),0.38−0.27(m,2H),0.25−0.14(m,2H).
1H NMR(500MHz,DMSO−d6)シフト 8.06−7.96(m,1H),7.36−7.25(m,1H),7.01−6.93(m,1H),6.87−6.79(m,1H),6.70−6.61(m,1H),4.44−4.37(m,2H),4.14−4.08(m,3H),4.01−3.95(m,3H),3.95−3.92(m,3H),3.54−3.43(m,1H),3.31−3.21(m,1H),3.06−2.96(m,1H),2.23−2.10(m,1H),1.94−1.84(m,2H),1.65−1.43(m,1H),1.21−1.06(m,1H),0.37−0.24(m,2H),0.23−0.11(m,2H).
スキーム13.1を用いて製造した。
tert−ブチル((1S,4R)−2−(2−(5−ブロモ−1−(シクロプロピルメチル)−1H−インドール−2−イル)−7−メトキシ−1−メチル−1H−ベンゾ[d]イミダゾール−5−カルボニル)−2−アザビシクロ[2.2.1]ヘプタン−7−イル)カルバメート5(50mg,0.077mmol)、(E)−(4−(トリフルオロメチル)スチリル)ボロン酸(16.65mg,0.077mmol)およびリン酸カリウム塩(III)(0.925mL,0.463mmol)/THF(5mL)の水溶液(0.5M)の懸濁液に、2−ジシクロヘキシルホスフィノ−2',6'−ジ−I−プロポキシ−1,1'ビフェニル(21.58mg,0.046mmol)および塩化パラジウム(II)(2.73mg,0.015mmol)を一度に加えた。得られる赤味がかった懸濁液を、80℃に4時間加熱した。反応溶液を、EtOAcで希釈して、H2O、塩水で洗い、乾燥させて(MgSO4)、濃縮して、淡い橙色のワックスを得た。このワックスは、LCMS(MW=739)により十分にきれいだったので、脱保護工程に進めた。ワックスを、DCM(2mL)に取り、次いで4M HCl(0.5mL,2.000mmol)(ジオキサン中で4M)で処理した。1時間後に、反応混合物を濃縮して、DCM中に取り、濾過して、乾燥させて(MgSO4)、濃縮して、次いで精製して、2ml DMF中で32mgを得た。粗製物質を、分取LC/MSにより精製した:カラム:XBridge C18,19 x 200mm, 5μm粒子;移動相A:5:95 アセトニトリル:水(10mM 酢酸アンモニウムを含む);移動相B:95:5 アセトニトリル:水(10mM 酢酸アンモニウムを含む);グラジエント:19分かけて50〜90%B、次いで100%Bで4分間保持した;流量:20mL/分。目的とする生成物を含有する画分を合わせて、遠心蒸発により乾燥させた。生成物の収量は20.3mg(34%収率)であり、LCMS分析によるその算出純度は100%であった。LCMS(方法B):保持時間2.42分間,M/z=640.14(M+1).
工程1:tert−ブチル((1S,4R)−2−(2−(5−シアノ−1−(シクロプロピルメチル)−1H−インドール−2−イル)−7−メトキシ−1−メチル−1H−ベンゾ[d]イミダゾール−5−カルボニル)−2−アザビシクロ[2.2.1]ヘプタン−7−イル)カルバメート:
Tert−ブチル((1S,4R)−2−(2−(6−ブロモ−1−(シクロプロピルメチル)−1H−インドール−2−イル)−7−メトキシ−1−メチル−1H−ベンゾ[d]イミダゾール−5−カルボニル)−2−アザビシクロ[2.2.1]ヘプタン−7−イル)カルバメート6:
方法A
(低pH Shimadzu 3分 方法)
カラム:Waters Acquity UPLC BEH dC18, 2.1mm x 50mm, 1.7μmカラム
流量:0.6ml/分
移動相:
A,TFA(水溶液)0.05%、および
B,TFA(アセトニトリル)0.05%
インジェクション量:3μl
温度;40℃
検出:220nm(ノミナル)
グラジエント−0〜100%B
カラム:Water Xbridge C18, 2.1mm x 50mm, 1.7μmカラム
流量:0.6ml/分
移動相:
アセトニトリル:水(10mM 酢酸アンモニウムを含む);
移動相B:
95:5 アセトニトリル:水(10mM 酢酸アンモニウムを含む);
温度:50℃;
グラジエント:3分かけて0%B〜100%B、次いで0.75分間100%Bで保持
インジェクション量:3μl
温度;40℃
検出:220nm(ノミナル)
本発明の化合物を、下記のアッセイプロトコルを用いてPAD4の阻害剤としてアッセイした。
反応容量:20μl
アッセイ緩衝液(前記の通り):100mM トリス−HCl(pH7.6),2mM DTT,1mM CaCl2
最終濃度:
−100nM hPAD4酵素
−50μM(8倍 Km以下)基質ペプチド
−0.5% DMSO
全インキュベーション時間:37℃で65分
停止溶液:40μl 5% TCA/ACN
化合物の溶液(0.25μL)を、アッセイ緩衝液(100mM トリス−HCl(pH7.6),2mM DTT)中で200nM PAD4(10μL)に加えた。5分後に、緩衝液(100mM トリス−HCl(pH7.6),2mM DTT,2mM CaCl2)中の100μM 基質(10μL)を加えて、この反応溶液を、60分間、37℃でインキュベートした。酵素反応を、5% TCA/ACN(1.7% TCA最終濃度)停止溶液(40μl)を添加することによりクエンチした。アルギニンを含有する基質およびシトルリンを含有する生成物(+1Da 質量シフト)を、Agilent RapidFire(RF) 300 System上の固相抽出物に付して、定量のために複数の反応のモニタリング(MRM)を用いて、二重極、三重極、四重極Agilent 6460 QQQ質量スペクトル分析(MS)装置で検出した。
所定の試験化合物についてのIC50を、マススペクトルアッセイを用いて測定して、これを、フェニルグリオキサールと反応後にBAEEのシトルリン化生成物を検出した。試験化合物を、100% DMSOに溶解して、0.125uLを、酵素添加の前に384ウェルのREMPポリプロピレンプレートに移した。酵素および化合物を、30分間37℃でプレインキュベートして、各アッセイウェル内の最終濃度が、カルシウム濃度が飽和している時点のBAEEについてのKm値と等しくなるようにBAEE基質を添加して(250uM)、反応を開始した。この反応に用いた緩衝液は、25mM Hepes(pH7.5)、5mM NaCl、1mM DTT、0.01% Chaps、0.2mg/mL BSA、ならびに50uMまたは1mM CaCl2のいずれか(これは、BAEEの10倍Kmで測定した場合に、各々Ca2+に対するK0.5またはCa2+に対する20xK0.5の5分の1に対応している)を含有する。使用した典型的な酵素濃度は、最終反応において5nMであり、全反応容量は25uLであった。反応を、BAEEを添加した後に1.5時間37℃で行い、その後15ulの6.1N TCAおよび35ulの8.5mM フェニルグリオキサールを用いてクエンチした。フェニルグリオキサールの最終濃度は、4mMであった。混合物を、攪拌しながら更に30分間37℃でインキュベートして、フェニルグリオキサールによるシトルリン化生成物の修飾を完了させた。クエンチした反応プレートを、3分間,5000xgで遠心分離して、内部標準(フェニルグリオキサール修飾シトルリン)を含む等量のメタノールを各ウェルに加えた。反応物を、Rapidfire MS分析のために新しい384ウェルREMPプレートに移した。
ここで、Y=各阻害剤濃度での阻害%、A=最小のY値、B=最大のY値、C=logIC50、D=ヒルスロープ、およびx=阻害剤濃度。
“E”として表される活性を示す化合物は、pIC50 <4を示す;“F”として表される活性を示す化合物は、4.0〜5.0のpIC50を提供する;“G”として表される活性を示す化合物は、5.0〜6.0のpIC50を提供する;“H”として表される活性を示す化合物は、>6のpIC50を提供する。“NA”は、“アッセイしていない”ことを表す。
Claims (21)
- 式I':
[式中、
環Aは、
であって、
環Aは、フッ素、−CN、−ORまたはC1−6脂肪族基(1〜3個のフッ素原子で所望により置換されていてもよい)から選択される1〜4つの基で所望により置換されていてもよい;
環Bは、
であり;
R1は、水素、−CN、−OR、
R2は、水素であるか、あるいはフッ素、−CNまたは−ORから選択される1〜5つの基で所望により置換されていてもよいC1−10脂肪族基であり;
X1およびX2の各々は、独立して、NまたはC(R4)から選択され;
R3は、ハロゲン、−CN、−R、
または−ORであり;
各R4は、独立して、ハロゲン、−CN、−R、
R5は、水素またはハロゲンであり;
nは0〜4であり;および
各Rは、独立して、水素であるか、あるいは1〜3個のフッ素原子で所望により置換されていてもよいC1−6脂肪族基である]
の化合物あるいはその医薬的に許容される塩。 - 環Aが、
- 環Aが、
- R1が、メチル、エチルまたはプロピルである、請求項1〜3のいずれか一項記載の化合物。
- R2が、1〜5個のフッ素原子で所望により置換されていてもよいC1−10脂肪族基である、請求項1〜4のいずれか一項記載の化合物。
- R2が、メチル、エチルまたは−CH2−シクロプロピルである、請求項5記載の化合物。
- R2が、1〜5個のフッ素原子で置換されたC1−10脂肪族基である、請求項5記載の化合物。
- R2が、−CH2CF3である、請求項7記載の化合物。
- X1およびX2の両者がNである、請求項1〜8のいずれか一項記載の化合物。
- X1がNであり、X2がCHである、請求項1〜8のいずれか一項記載の化合物。
- X1がCHであり、X2がNである、請求項1〜8のいずれか一項記載の化合物。
- X1およびX2の両者がCHである、請求項1〜8のいずれか一項記載の化合物。
- R4が、C1−6脂肪族基または−ORである、請求項1〜12のいずれか一項記載の化合物。
- R4が、エチルまたは−OCH3である、請求項13記載の化合物。
- 請求項1〜14のいずれか一項記載の化合物、および医薬的に許容し得る担体、アジュバンドまたはビヒクルを含む、医薬的に許容し得る組成物。
- 別の治療薬と組み合わせる、請求項15記載の組成物。
- PAD4を、請求項1〜14のいずれか一項記載の化合物と接触させる工程を特徴とする、対象または生物学的試料中のPAD4を阻害する方法。
- PAD4介在性の疾患、障害または症状を治療する方法であって、前記対象に請求項15記載の組成物を投与する工程を特徴とする、方法。
- 前記対象がヒト対象である、請求項18記載の方法。
- PAD4介在性疾患、障害または症状は、酸誘発性肺傷害、座瘡(PAPA)、急性リンパ性白血病、急性呼吸窮迫症候群、アジソン病、副腎過形成、副腎皮質機能不全、老化、エイズ、アルコール性肝炎、アルコール性肝炎、アルコール性肝疾患、アレルギー性喘息、アレルギー性気管支肺アスペルギルス症、アレルギー性結膜炎、脱毛症、アルツハイマー病、アミロイドーシス、筋萎縮性側索硬化症および体重減少、狭心症、血管性浮腫、無汗性外胚葉形成不全症(AHED-ID)、強直性脊椎炎、前眼部炎症、抗リン脂質症候群、アフタ性口内炎、虫垂炎、関節炎、喘息、アテローム性動脈硬化症、アトピー性皮膚炎、自己免疫性疾患、自己免疫性肝炎、蜂刺傷誘発炎症、ベーチェット病、ベーチェット症候群、ベル麻痺、ベリリウム中毒症、ブラウ症候群、骨痛、細気管支炎、火傷、滑液包炎、癌、心臓肥大、手根管症候群、異化障害、白内障、脳動脈瘤、化学的刺激物誘発性炎症、脈絡網膜炎、慢性心疾患、未熟児の慢性肺疾患、慢性リンパ性白血病、慢性閉塞性肺疾患、大腸炎、複合性局所疼痛症候群、膠原病、角膜潰瘍、クローン病、クリオピリン関連周期熱症候群、クリプトコッカス症、嚢胞性線維症、インターロイキン-1-受容体アンタゴニスト(DIRA)欠損症、皮膚炎、皮膚炎内毒素血症、皮膚筋炎、小児脳幹部グリオーマ、子宮内膜症、内毒素血症、上顆炎、赤芽球減少症、家族性アミロイド多発性神経障害、家族性寒冷蕁麻疹、家族性地中海熱、胎児発育遅延、緑内障、糸球体疾患、糸球体腎炎、痛風、痛風性関節炎、移植片対宿主病、消化器疾患、頭部外傷、頭痛、難聴、心臓病、溶血性貧血、ヘノッホ・シェーライン紫斑病、肝炎、遺伝性自己炎症症候群、帯状疱疹と単純ヘルペス、HIV-1、ホジキン病、ハンチントン病、肺硝子膜症、高アンモニア血症、高カルシウム血症、高コレステロール血症、周期熱(HIDS)を伴う高免疫グロブリン血症D症候群、再生不良性貧血および他の貧血、再生不良性貧血、特発性血小板減少性紫斑病、色素失調症、伝染性単核球症、炎症性腸疾患、炎症性肺疾患、炎症性神経障害、炎症性疼痛、虫刺さ誘発性炎症、虹彩炎、刺激性誘発性炎症、虚血/再灌流、若年性関節リウマチ、角膜炎、腎臓病、寄生虫感染により起こる腎障害、寄生虫感染を引き起こす腎障害、腎臓移植拒絶反応の予防、レプトスピラ症、白血病、レフラー症候群、肺外傷、肺外傷、狼瘡、狼瘡、狼瘡性腎炎、リンパ腫、髄膜炎、中皮腫、混合型膠原病、マックルウェルズ症候群(蕁麻疹の難聴アミロイドーシス)、多発性硬化症、筋肉疲労、筋ジストロフィー、重症筋無力症、心筋炎、菌状息肉症、菌状息肉腫、骨髄異形成症候群、筋炎、鼻副鼻腔炎、壊死性全腸炎、新生児期発症多臓器性炎症性疾患(NOMID)、ネフローゼ症候群、神経炎、神経病理学的疾患、非アレルギー誘導性の喘息、肥満、眼アレルギー、視神経炎、臓器移殖、骨関節炎、中耳炎、ページェット病、疼痛、膵炎、パーキンソン病、天疱瘡、心膜炎、周期熱、歯周炎、腹膜子宮内膜症、百日咳、咽頭炎やリンパ節炎(PFAPA症候群)、植物刺激誘発性炎症、肺炎(pneumonia)、肺臓炎(pneumonitis)、ニューモシスチス肺炎、アメリカツタウルシ/ウルシオール油誘導性炎症、結節性多発動脈、多発軟骨炎、多発性嚢胞腎疾患、多発性筋炎、乾癬、乾癬、乾癬、乾癬、心理社会的ストレス疾患、肺疾患、肺高血圧症、肺線維症、壊疽性膿皮症、化膿性関節炎、腎疾患、網膜疾患、リウマチ性心炎、リウマチ性疾患、リウマチ性関節炎、サルコイドーシス、脂漏症、敗血症、激痛、鎌状赤血球、鎌状赤血球貧血、シリカ誘発性疾患、シェーグレン症候群、皮膚疾患、睡眠時無呼吸、固形腫瘍、脊髄損傷、スティーヴンス・ジョンソン症候群、卒中、クモ膜下出血、日焼け、側頭動脈炎、腱滑膜炎、血小板減少症、甲状腺炎、組織移植、TNF受容体関連周期性症候群(TRAPS)、トキソプラズマ症、移殖、外傷性脳損傷、結核、I型糖尿病、II型糖尿病、潰瘍性大腸炎、蕁麻疹様ブドウ膜炎、ブドウ膜炎およびウェゲナー肉芽腫症からなる群から選択される、請求項18記載の方法。
- PAD4介在性疾患、障害または症状が、関節リウマチ関節炎、血管炎、全身性エリテマトーデス、潰瘍性大腸炎、癌、嚢胞性線維症、喘息、皮膚エリテマトーデスおよび乾癬から選択される、請求項18記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264925P | 2015-12-09 | 2015-12-09 | |
US62/264,925 | 2015-12-09 | ||
PCT/US2016/065857 WO2017100594A1 (en) | 2015-12-09 | 2016-12-09 | Bicyclic inhibitors of pad4 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019505568A true JP2019505568A (ja) | 2019-02-28 |
JP2019505568A5 JP2019505568A5 (ja) | 2020-01-16 |
JP6932136B2 JP6932136B2 (ja) | 2021-09-08 |
Family
ID=59013640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018549402A Active JP6932136B2 (ja) | 2015-12-09 | 2016-12-09 | Pad4の二環式阻害剤 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9963448B2 (ja) |
EP (2) | EP3386590B1 (ja) |
JP (1) | JP6932136B2 (ja) |
KR (1) | KR20180098574A (ja) |
CN (1) | CN109069869B (ja) |
AR (1) | AR107032A1 (ja) |
AU (1) | AU2016366398A1 (ja) |
BR (1) | BR112018011709A2 (ja) |
CA (1) | CA3007639A1 (ja) |
EA (1) | EA201891251A1 (ja) |
ES (1) | ES2877543T3 (ja) |
IL (1) | IL259794A (ja) |
MX (1) | MX2018006632A (ja) |
SG (1) | SG11201804668UA (ja) |
TW (1) | TW201726674A (ja) |
UY (1) | UY37018A (ja) |
WO (1) | WO2017100594A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018520105A (ja) * | 2015-05-21 | 2018-07-26 | グラクソスミスクライン、インテレクチュアル、プロパテ | Pad4阻害剤としてのベンゾイミダゾール誘導体 |
JP2019505597A (ja) * | 2016-02-23 | 2019-02-28 | パドロック・セラピューティクス・インコーポレイテッド | Pad4のヘテロアリール阻害剤 |
JP2023524036A (ja) * | 2020-04-30 | 2023-06-08 | ギリアード サイエンシーズ, インコーポレイテッド | ペプチジルアルギニンデイミナーゼの大環状阻害剤 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2828623T3 (es) | 2016-07-27 | 2021-05-27 | Padlock Therapeutics Inc | Inhibidores covalentes de PAD4 |
MA46193A (fr) | 2016-09-12 | 2019-07-17 | Padlock Therapeutics Inc | Inhibiteurs hétéroaryles de pad4 |
TWI762769B (zh) * | 2018-02-26 | 2022-05-01 | 大陸商藥捷安康(南京)科技股份有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
JP7447080B2 (ja) * | 2018-08-08 | 2024-03-11 | ブリストル-マイヤーズ スクイブ カンパニー | Pad4阻害剤としての置換チエノピロール |
PE20211067A1 (es) | 2018-08-08 | 2021-06-09 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de pad4 |
CA3108791A1 (en) * | 2018-08-08 | 2020-02-13 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
US20220348562A1 (en) * | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
WO2020194160A1 (en) | 2019-03-28 | 2020-10-01 | Lupin Limited | Macrocyclic compounds as sting agonists |
WO2021057910A1 (zh) * | 2019-09-27 | 2021-04-01 | 南京药捷安康生物科技有限公司 | 肽酰精氨酸脱亚胺酶抑制剂及其用途 |
EP4100405A1 (en) * | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
CN112618546B (zh) * | 2020-12-22 | 2022-03-01 | 陈昊 | Pad4抑制剂在制备放射治疗增敏药物方面的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522628A (ja) * | 2012-07-26 | 2015-08-06 | グラクソ グループ リミテッドGlaxo Group L | Pad4阻害剤としての2−(アザインドール−2−イル)ベンズイミダゾール |
WO2016185279A1 (en) * | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
WO2004041277A1 (en) | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
EP2234486A4 (en) | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER |
WO2012061390A2 (en) * | 2010-11-01 | 2012-05-10 | The Penn State Research Foundation | Therapeutic compositions and methods |
JP5721484B2 (ja) | 2011-03-17 | 2015-05-20 | 富士フイルム株式会社 | 重合性液晶組成物、それを用いた高分子材料および光学異方性フィルム、並びに重合性液晶化合物 |
WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CN104428293B (zh) | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
AP3902A (en) * | 2012-06-29 | 2016-11-17 | Pfizer | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
-
2016
- 2016-12-07 AR ARP160103778A patent/AR107032A1/es unknown
- 2016-12-08 TW TW105140709A patent/TW201726674A/zh unknown
- 2016-12-09 WO PCT/US2016/065857 patent/WO2017100594A1/en active Application Filing
- 2016-12-09 CA CA3007639A patent/CA3007639A1/en not_active Abandoned
- 2016-12-09 AU AU2016366398A patent/AU2016366398A1/en not_active Abandoned
- 2016-12-09 US US15/374,159 patent/US9963448B2/en active Active
- 2016-12-09 ES ES16873928T patent/ES2877543T3/es active Active
- 2016-12-09 EP EP16873928.2A patent/EP3386590B1/en active Active
- 2016-12-09 CN CN201680081403.0A patent/CN109069869B/zh active Active
- 2016-12-09 UY UY0001037018A patent/UY37018A/es unknown
- 2016-12-09 MX MX2018006632A patent/MX2018006632A/es unknown
- 2016-12-09 BR BR112018011709A patent/BR112018011709A2/pt not_active Application Discontinuation
- 2016-12-09 KR KR1020187019382A patent/KR20180098574A/ko not_active Application Discontinuation
- 2016-12-09 EP EP21171167.6A patent/EP3885342A1/en active Pending
- 2016-12-09 JP JP2018549402A patent/JP6932136B2/ja active Active
- 2016-12-09 EA EA201891251A patent/EA201891251A1/ru unknown
- 2016-12-09 SG SG11201804668UA patent/SG11201804668UA/en unknown
-
2018
- 2018-06-04 IL IL259794A patent/IL259794A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522628A (ja) * | 2012-07-26 | 2015-08-06 | グラクソ グループ リミテッドGlaxo Group L | Pad4阻害剤としての2−(アザインドール−2−イル)ベンズイミダゾール |
WO2016185279A1 (en) * | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
Non-Patent Citations (1)
Title |
---|
NAT CHEM BIOL., vol. 11, no. 3, JPN6020043539, March 2015 (2015-03-01), pages 189 - 191, ISSN: 0004461947 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018520105A (ja) * | 2015-05-21 | 2018-07-26 | グラクソスミスクライン、インテレクチュアル、プロパテ | Pad4阻害剤としてのベンゾイミダゾール誘導体 |
JP2019505597A (ja) * | 2016-02-23 | 2019-02-28 | パドロック・セラピューティクス・インコーポレイテッド | Pad4のヘテロアリール阻害剤 |
JP2023524036A (ja) * | 2020-04-30 | 2023-06-08 | ギリアード サイエンシーズ, インコーポレイテッド | ペプチジルアルギニンデイミナーゼの大環状阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
AU2016366398A1 (en) | 2018-07-19 |
CN109069869A (zh) | 2018-12-21 |
AR107032A1 (es) | 2018-03-14 |
EP3885342A1 (en) | 2021-09-29 |
US9963448B2 (en) | 2018-05-08 |
EP3386590A1 (en) | 2018-10-17 |
CA3007639A1 (en) | 2017-06-15 |
MX2018006632A (es) | 2018-11-09 |
TW201726674A (zh) | 2017-08-01 |
WO2017100594A1 (en) | 2017-06-15 |
EA201891251A1 (ru) | 2018-12-28 |
BR112018011709A2 (pt) | 2018-12-04 |
CN109069869B (zh) | 2022-09-13 |
IL259794A (en) | 2018-08-30 |
KR20180098574A (ko) | 2018-09-04 |
ES2877543T3 (es) | 2021-11-17 |
EP3386590B1 (en) | 2021-06-02 |
UY37018A (es) | 2017-06-30 |
SG11201804668UA (en) | 2018-06-28 |
US20170166565A1 (en) | 2017-06-15 |
EP3386590A4 (en) | 2019-10-16 |
JP6932136B2 (ja) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6932136B2 (ja) | Pad4の二環式阻害剤 | |
JP7041198B2 (ja) | Jak阻害剤である5-クロロ-2-ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
TWI763722B (zh) | Tyk2抑制劑及其用途 | |
JP6802263B2 (ja) | Tyk2阻害剤およびその使用 | |
KR102398941B1 (ko) | Pad4의 공유결합성 억제제 | |
KR101793807B1 (ko) | 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물 | |
JP2019505597A (ja) | Pad4のヘテロアリール阻害剤 | |
US20220356185A1 (en) | Mertk degraders and uses thereof | |
KR20190112265A (ko) | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 | |
JP2022547719A (ja) | Hpk1アンタゴニストおよびその使用 | |
KR20200143376A (ko) | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 | |
KR20220145325A (ko) | Irak 분해제 및 이의 용도 | |
CN108601770B (zh) | Pad4的氮杂-苯并咪唑抑制剂 | |
TW202233612A (zh) | Ctps1抑制劑及其用途 | |
EA030472B1 (ru) | ПИРРОЛО[2,3-d]ПИРИМИДИНИЛ-, ПИРРОЛО[2,3-b]ПИРАЗИНИЛ- И ПИРРОЛО[2,3-d]ПИРИДИНИЛАКРИЛАМИДЫ | |
EP3833350A1 (en) | Pyrrolopyrimidine itk inhibitors | |
TWI762534B (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
CA3095367A1 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
KR20220151160A (ko) | Smarca 분해제 및 이의 용도 | |
AU2009235729A1 (en) | Thienopyrimidines | |
JP2023528421A (ja) | キナーゼ阻害剤 | |
WO2023083365A1 (en) | Pad4 inhibitors and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191128 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191128 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210408 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210810 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210817 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6932136 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |